title: WLSSD_100perc_Ovary_48h_3_X_Y_Z

status: Public on Jul 06 2016

city: Vicksburg

first: Natalia

last: Vinas

state: MS

address: 3909 Halls Ferry Rd

institute: Mississippi State University

description:
chemical abbreviations: BPA, bisphenol-A; EE2, 17a-ethynyl estradiol;  FAD, fadrozole; FLU, flutamide; GEM, Gemfibrozil; KTC, ketoconazole; PRO, prochloraz; RDX, hexahydro-1,3,5-trinitro-1,3,5-triazine; TB, 17 -trenbolone; TCC, triclocarban; TNT, 2,4,6-trinitrotoluene; TRI,trilostane; VIN, vinclozolin; WLSSD, effluent from Western Lake Superior Sanitary District
Exposure duration abbreviations: D, day; H, hour; M, minute; HP, hours post exposure ; DP, days post exposure ; ACT, acute
Naming convention for sample names with multiple chemicals: Relative to the corresponding controls, additional chemcials present in a treated sample indicate its exposure conditions.  For example, compared to KTCTNT_Control_Ovary_024h1h_1_X_Y_Z, the treated sample KTCTNTKTC_0.5_Ovary_024h1h_1_X_Y_Z was exposed to the chemical KTC.  Similarly, with TbBPA_Control_Ovary_14d_1_X_Y_Z indicating a control sample, the sample TbBPATbBPA_10_Ovary_14d_1_X_Y_Z was exposed to both Tb and BPA.

hyb_protocol: The Agilent one-color microarray hybridization protocol (One-Color Microarray-Based Gene Expression Analysis, version 5.7, Agilent Technologies, Palo Alto, CA) was used for microarray hybridizations following the manufacturer’s protocol and recommendations.

scan_protocol: An Axon GenePix® 4000A/B Microarray Scanner (Molecular Devices Inc.) was used to scan microarray images at 5 µm resolution

data_processing: Microarray image processing was performed using the latest Agilent's Feature Extraction software available at the time (version 9.5) following the manufacturer’s protocol and recommendations.  Data processing was conducted using R package Limma, in the order of backgroundCorrect(normexp) and normalizeBetweenArrays(quantile).

organism: Pimephales promelas

source_name: ovary tissue, fish exposed to various treatment conditions

label_protocol: cDNA synthesis, cRNA labeling, amplification and hybridization were performed following the manufacturer's kits and protocols (Quick Amp Labeling Kit; Agilent, Palo Alto, CA)

growth_protocol: Sexually mature adult fathead minnows (5-6 month old) were obtained from an on-site aquatic culture facility at the US EPA Mid-Continent Ecology Division, Duluth, MN, USA. Fish were held under a 16:8 light:dark photoperiod fed frozen adult brine shrimp (San Francisco Bay Brand, Newark, CA, USA). Fish survival, water temperature (mean ± SD; 25.0±0.3), and dissolved oxygen (mean ± SD; 7.0±0.2) were monitored daily over the duration of the exposure and did not vary significantly between treatment groups.

extract_protocol: Total RNA was isolated from ovary tissue of both fathead minnow using RNeasy kits (Qiagen, Valencia, CA, USA). RNA quality was evaluated using an Agilent 2100 Bioanalyzer (Agilent, Wilmington, DE, USA) and RNA was quantified spectrophotometrically (Nanodrop). Total RNA samples were stored at -80oC until used for microarray analyses.

treatment_protocol: To initiate a typical experiment, four males and four females were placed together in a glass test tank holding 10 L of Lake Superior water (4 µM filtered, UV sterilized) or test chemical dissolved in Lake Superior water, which was continuously renewed at a rate of about 45 mL/min. There were two such tanks for each treatment condition. The animals were held at 25 +/- 0.5 °C under a 16:8 L:D photoperiod, and were fed brine shrimp to satiation twice per day.

tag: chemical

value: WLSSD

tag: dose

tag: tissue

value: OVARY

tag: exposure duration

tag: dosage unit

value: % of effluent

tag: age (month)

tag: arrayname

tag: featureextractiontime


title: WLSSD_50perc_Ovary_48h_4_X_Y_Z

type: RNA

country: USA

molecule: total RNA


title: WLSSD_50perc_Ovary_48h_3_X_Y_Z


title: WLSSD_50perc_Ovary_48h_1_X_Y_Z


title: WLSSD_50perc_Ovary_48h_2_X_Y_Z


title: WLSSD_100perc_Ovary_48h_1_X_Y_Z


title: WLSSD_10perc_Ovary_48h_5_X_Y_Z


title: WLSSD_100perc_Ovary_48h_2_X_Y_Z


title: WLSSD_10perc_Ovary_48h_2_X_Y_Z


title: PHF1

status: Public on Jul 07 2016

type: genomic

city: Tianjin

first: Yan

last: Wang

address: #22 Qixiangtai Road

department: Department of Biochemistry and Molecular Biology

country: China

institute: Tianjin Medical University

description: Chip-chip MDA-MB-231 cells PHF1

hyb_protocol: The labeled ChIP DNA was precipitated with 0.1 volume 5M NaCl and 1 volume isopropanol, and hybridized in 45 ul of buffer containing 20% formamide, 1.2 M betaine, 0.1 ug/ul herring sperm DNA and 10 ug of human COT1 DNA (Invitrogen). Arrays were hybridized in Maui hybridization stations for 16-18 h at 42C, and then washed in 42C 0.2% SDS/0.2x SSC, room temperature 0.2x SSC, and 0.05x SSC. Hybridization buffers and washes were completed using manufacturer's protocols (http://www.nimblegen.com/products/lit/lit.html)

scan_protocol: Arrays were scanned on an Axon 4000B scanner per manufacturer's protocol (http://www.nimblegen.com/products/lit/lit.html).

data_processing: Raw data were extracted as pair files by NimbleScan software. We performed Median-centering, quantile normalization, and linear smoothing by Bioconductor packages Ringo, limma and MEDME. After normalization, a normalized log2-ratio data was created for each sample. From the normalized log2-ratio data, a permutation-based peak-finding algorithm provided by NimbleScan v2.5 (Roche-NimbleGen) was applied to find peaks which represent significant positive enrichment. NimbleScan detects peaks by searching for 4 or more probes whose signals were above the specified cutoff values, ranging from 90% to 15%, using a 500bp sliding window. The cutoff values are a percentage of a hypothetical maximum, which is the mean + 6[standard deviation]. The ratio data is then randomized 20 times to evaluate the probability of “false positives”.

molecule: genomic DNA

organism: Homo sapiens

source_name: PHF1 ChIP DNA from MDA-MB-231 cells

label_protocol: 1 µg ChIP DNA was directly labeled by Klenow (New England Biolabs) random priming with Cy3 nonamers (ChIP DNA isolated from normal rabbit IgG-immunoprecipitated cells) per manufacturer's protocol (http://www.nimblegen.com/products/lit/lit.html).

growth_protocol: MDA-MB-231 cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Invitrogen). All media contained 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 mg/ml streptomycin (Gibco BRL).

extract_protocol: 1x10E7 cells were washed twice with PBS and cross-linked with 1% formaldehyde at room temperature for 10 min. Cells then were rinsed with ice-cold PBS twice and collected into 100 mM Tris-HCl (pH 9.4), 10 mM DTT and incubated for 15 min at 30°C and centrifuged for 5 min at 2000 g. Cells were washed sequentially with 1 ml of ice-cold PBS, buffer I (0.25% Triton X-100, 10 mM EDTA, 0.5 mM EGTA, 10 mM HEPES, pH 6.5), and buffer II (200 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 10 mM HEPES, pH 6.5). Cells were then resuspended in 0.3 ml of lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.1, 1× protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN) and sonicated three times for 10 s each at the maximum setting (Fisher Sonic Dismembrator, Model 300) followed by centrifugation for 10 min. Supernatants were collected and diluted in buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris-HCl, pH 8.1) followed by immunoclearing with 2 μg sheared salmon sperm DNA, 20 μl preimmune serum and protein A-sepharose (45 μl of 50% slurry in 10 mM Tris-HCl, pH 8.1, 1 mM EDTA) for 2 hr at 4°C. Immunoprecipitation was performed for 6 hr or overnight at 4°C with specific antibodies. After immunoprecipitation, 45 μl protein A-Sepharose and 2 μg of salmon sperm DNA were added and the incubation was continued for another 1 hr. Precipitates were washed sequentially for 10 min each in TSE I (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl), TSE II (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl), and buffer III (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl, pH 8.1). Precipitates were then washed three times with TE buffer and extracted three times with 1% SDS, 0.1 M NaHCO3. Eluates were pooled and heated at 65°C for at least 6 hr to reverse the formaldehyde cross-linking. DNA fragments were purified with a QIAquick Spin Kit (Qiagen, CA). For PCR, 1 μl from a 50 μl DNA extraction and 21–25 cycles of amplification were used.

treatment_protocol: 1x10E7 cells were collected for ChIP assay per antibody

tag: cell line

tag: chip antibody

tag: chip antibody vendor

value: abcam

tag: chip antibody cat. #

tag: chip antibody lot #

source_name: Input DNA from MDA-MB-231 cells

value: none, input DNA


title: WLSWSD_LSWControl_Ovary_48h_1_X_Y_Z

value: WLSWSD

value: LSWCONTROL


title: VZ_700_Ovary_96hp_D_Phase3_Y_Z

value: VZ

value: ug/L


title: WLSWSD_LSWControl_Ovary_48h_5_X_Y_Z


title: WLSWSD_LSWControl_Ovary_48h_4_X_Y_Z


title: VZ_200_Ovary_96hp_C_Phase3_Y_Z


title: VZ_200_Ovary_96hp_B_Phase3_Y_Z


title: WLSSD_10perc_Ovary_48h_3_X_Y_Z


title: WLSSD_10perc_Ovary_48h_4_X_Y_Z


title: WLSSD_100perc_Ovary_48h_4_X_Y_Z


title: VZ_200_Ovary_96hp_D_Phase3_Y_Z


title: VZ_700_Ovary_96hp_A_Phase3_Y_Z


title: WLSWSD_LSWControl_Ovary_48h_2_X_Y_Z


title: VZ_700_Ovary_96hp_B_Phase3_Y_Z


title: VZ_200_Ovary_96hp_A_Phase3_Y_Z


title: WLSWSD_LSWControl_Ovary_48h_3_X_Y_Z


title: VZ_700_Ovary_96hp_C_Phase3_Y_Z


title: VZ_Control_Ovary_96hp_D_Phase3_Y_Z

value: CONTROL


title: VZ_Control_Ovary_96hp_B_Phase3_Y_Z


title: VZ_Control_Ovary_96hp_C_Phase3_Y_Z


title: VZ_200_Ovary_96h_D_Phase3_Y_Z


title: VZ_700_Ovary_96h_C_Phase3_Y_Z


title: VZ_200_Ovary_96h_C_Phase3_Y_Z


title: VZ_700_Ovary_96h_D_Phase3_Y_Z


title: VZ_700_Ovary_48hp_D_Phase3_Y_Z


title: VZ_700_Ovary_96h_B_Phase3_Y_Z


title: VZ_700_Ovary_48hp_B_Phase3_Y_Z


title: VZ_200_Ovary_96h_B_Phase3_Y_Z


title: VZ_Control_Ovary_96h_C_Phase3_Y_Z


title: VZ_200_Ovary_48hp_C_Phase3_Y_Z


title: VZ_Control_Ovary_96h_D_Phase3_Y_Z


title: VZ_Control_Ovary_48hp_B_Phase3_Y_Z


title: VZ_200_Ovary_48hp_A_Phase3_Y_Z


title: VZ_Control_Ovary_96h_B_Phase3_Y_Z


title: VZ_200_Ovary_48hp_D_Phase3_Y_Z


title: VZ_Control_Ovary_48hp_C_Phase3_Y_Z


title: VZ_Control_Ovary_48hp_A_Phase3_Y_Z


title: VZ_700_Ovary_96h_A_Phase3_Y_Z


title: VZ_200_Ovary_96h_A_Phase3_Y_Z


title: VZ_700_Ovary_48h_D_Phase3_Y_Z


title: VZ_Control_Ovary_48hp_D_Phase3_Y_Z


title: VZ_700_Ovary_48hp_A_Phase3_Y_Z


title: VZ_Control_Ovary_96h_A_Phase3_Y_Z


title: VZ_200_Ovary_48h_D_Phase3_Y_Z


title: VZ_700_Ovary_48h_C_Phase3_Y_Z


title: VZ_700_Ovary_48hp_C_Phase3_Y_Z


title: VZ_700_Ovary_48h_B_Phase3_Y_Z


title: VZ_200_Ovary_48hp_B_Phase3_Y_Z


title: VZ_Control_Ovary_96hp_A_Phase3_Y_Z


title: VZ_200_Ovary_48h_A_Phase3_Y_Z


title: VZ_700_Ovary_48h_A_Phase3_Y_Z


title: VZ_200_Ovary_48h_B_Phase3_Y_Z


title: VZ_Control_Ovary_48h_D_Phase3_Y_Z


title: VZ_200_Ovary_48h_C_Phase3_Y_Z


title: VZ_Control_Ovary_48h_B_Phase3_Y_Z


title: VZ_700_Ovary_24hp_B_Phase3_Y_Z


title: VZ_Control_Ovary_48h_C_Phase3_Y_Z


title: VZ_700_Ovary_24hp_D_Phase3_Y_Z


title: VZ_700_Ovary_24hp_C_Phase3_Y_Z


title: VZ_Control_Ovary_48h_A_Phase3_Y_Z


title: VZ_200_Ovary_24hp_D_Phase3_Y_Z


title: VZ_Control_Ovary_24hp_C_Phase3_Y_Z


title: VZ_200_Ovary_24hp_A_Phase3_Y_Z


title: VZ_200_Ovary_24hp_B_Phase3_Y_Z


title: VZ_700_Ovary_24hp_A_Phase3_Y_Z


title: VZ_700_Ovary_24h_A_Phase3_Y_Z


title: VZ_Control_Ovary_24h_D_Phase3_Y_Z


title: VZ_200_Ovary_24h_A_Phase3_Y_Z


title: VZ_Control_Ovary_24hp_B_Phase3_Y_Z


title: VZ_Control_Ovary_24hp_A_Phase3_Y_Z


title: VZ_Control_Ovary_24h_C_Phase3_Y_Z


title: VZ_200_Ovary_24hp_C_Phase3_Y_Z


title: VZ_Control_Ovary_24hp_D_Phase3_Y_Z


title: VZ_700_Ovary_24h_C_Phase3_Y_Z


title: VZ_Control_Ovary_24h_A_Phase3_Y_Z


title: VZ_700_Ovary_24h_D_Phase3_Y_Z


title: VZ_200_Ovary_24h_C_Phase3_Y_Z


title: VZ_200_Ovary_24h_B_Phase3_Y_Z


title: VZ_700_Ovary_24h_B_Phase3_Y_Z


title: VZ_200_Ovary_24h_D_Phase3_Y_Z


title: VZ_700_Ovary_192hp_D_Phase3_Y_Z


title: VZ_700_Ovary_192hp_C_Phase3_Y_Z


title: VZ_200_Ovary_192hp_A_Phase3_Y_Z


title: VZ_200_Ovary_192hp_B_Phase3_Y_Z


title: VZ_Control_Ovary_192hp_D_Phase3_Y_Z


title: VZ_200_Ovary_192hp_D_Phase3_Y_Z


title: VZ_Control_Ovary_192hp_C_Phase3_Y_Z


title: VZ_700_Ovary_192hp_B_Phase3_Y_Z


title: VZ_200_Ovary_192hp_C_Phase3_Y_Z


title: VZ_700_Ovary_192hp_A_Phase3_Y_Z


title: VZ_Control_Ovary_192hp_B_Phase3_Y_Z


title: VZ_Control_Ovary_24h_B_Phase3_Y_Z


title: VZ_700_Ovary_192h_D_Phase3_Y_Z


title: VZ_Control_Ovary_192hp_A_Phase3_Y_Z


title: VZ_700_Ovary_192h_A_Phase3_Y_Z


title: VZ_200_Ovary_192h_C_Phase3_Y_Z


title: VZ_200_Ovary_192h_D_Phase3_Y_Z


title: VZ_700_Ovary_192h_B_Phase3_Y_Z


title: VZ_385_Ovary_ACT8h_C_X_Y_Z


title: VZ_Control_Ovary_192h_C_Phase3_Y_Z


title: VZ_Control_Ovary_192h_D_Phase3_Y_Z


title: VZ_Control_Ovary_192h_A_Phase3_Y_Z


title: VZ_385_Ovary_ACT8h_D_X_Y_Z


title: VZ_200_Ovary_192h_B_Phase3_Y_Z


title: VZ_385_Ovary_ACT8h_A_X_Y_Z


title: VZ_Control_Ovary_ACT8h_D_X_Y_Z


title: VZ_Control_Ovary_192h_B_Phase3_Y_Z


title: VZ_700_Ovary_192h_C_Phase3_Y_Z


title: VZ_200_Ovary_192h_A_Phase3_Y_Z


title: VZ_Control_Ovary_ACT8h_C_X_Y_Z


title: VZ_Control_Ovary_ACT8h_A_X_Y_Z


title: WLSSD_10perc_Ovary_48h_1_X_Y_Z


title: VZ_Control_Ovary_ACT8h_B_X_Y_Z


title: VZ_385_Ovary_ACT4h_D_X_Y_Z


title: VZ_385_Ovary_ACT8h_B_X_Y_Z


title: VZ_385_Ovary_ACT4h_C_X_Y_Z


title: VZ_385_Ovary_ACT2h_B_X_Y_Z


title: VZ_385_Ovary_ACT4h_B_X_Y_Z


title: VZ_385_Ovary_ACT2h_A_X_Y_Z


title: VZ_Control_Ovary_ACT4h_A_X_Y_Z


title: VZ_385_Ovary_ACT2h_D_X_Y_Z


title: VZ_385_Ovary_ACT2h_C_X_Y_Z


title: VZ_385_Ovary_ACT4h_A_X_Y_Z


title: VZ_Control_Ovary_ACT4h_B_X_Y_Z


title: VZ_385_Ovary_ACT1h_D_X_Y_Z


title: VZ_Control_Ovary_ACT4h_D_X_Y_Z


title: VZ_Control_Ovary_ACT2h_B_X_Y_Z


title: VZ_Control_Ovary_ACT1h_C_X_Y_Z


title: VZ_Control_Ovary_ACT12h_D_X_Y_Z


title: VZ_Control_Ovary_ACT2h_D_X_Y_Z


title: VZ_385_Ovary_ACT1h_C_X_Y_Z


title: VZ_385_Ovary_ACT1h_B_X_Y_Z


title: VZ_Control_Ovary_ACT2h_A_X_Y_Z


title: VZ_Control_Ovary_ACT1h_D_X_Y_Z


title: VZ_385_Ovary_ACT1h_A_X_Y_Z


title: VZ_385_Ovary_ACT12h_A_X_Y_Z


title: VZ_385_Ovary_ACT12h_B_X_Y_Z


title: VZ_Control_Ovary_ACT1h_B_X_Y_Z


title: VZ_Control_Ovary_ACT12h_C_X_Y_Z


title: VZ_Control_Ovary_ACT4h_C_X_Y_Z


title: VZ_385_Ovary_ACT12h_D_X_Y_Z


title: VZ_Control_Ovary_ACT2h_C_X_Y_Z


title: VZ_Control_Ovary_ACT12h_A_X_Y_Z


title: VZ_Control_Ovary_ACT1h_A_X_Y_Z


title: VZ_Control_Ovary_ACT12h_B_X_Y_Z


title: TRI_300_Ovary_96hp_A_Phase3_Y_Z

value: TRI


title: TRI_300_Ovary_96hp_B_Phase3_Y_Z


title: TRI_Control_Ovary_96hp_C_Phase3_Y_Z


title: TRI_1500_Ovary_96hp_D_Phase3_Y_Z


title: TRI_Control_Ovary_96hp_D_Phase3_Y_Z


title: TRI_1500_Ovary_96hp_B_Phase3_Y_Z


title: VZ_385_Ovary_ACT12h_C_X_Y_Z


title: TRI_300_Ovary_96hp_D_Phase3_Y_Z


title: TRI_1500_Ovary_96hp_A_Phase3_Y_Z


title: TRI_300_Ovary_96hp_C_Phase3_Y_Z


title: TRI_300_Ovary_96h_D_Phase3_Y_Z


title: TRI_Control_Ovary_96hp_A_Phase3_Y_Z


title: TRI_1500_Ovary_96h_D_Phase3_Y_Z


title: TRI_300_Ovary_96h_B_Phase3_Y_Z


title: TRI_300_Ovary_96h_A_Phase3_Y_Z


title: TRI_Control_Ovary_96hp_B_Phase3_Y_Z


title: TRI_300_Ovary_96h_C_Phase3_Y_Z


title: TRI_1500_Ovary_96hp_C_Phase3_Y_Z


title: TRI_Control_Ovary_96h_A_Phase3_Y_Z


title: TRI_Control_Ovary_96h_D_Phase3_Y_Z


title: TRI_300_Ovary_48hp_A_Phase3_Y_Z


title: TRI_1500_Ovary_96h_A_Phase3_Y_Z


title: TRI_Control_Ovary_96h_C_Phase3_Y_Z


title: TRI_Control_Ovary_96h_B_Phase3_Y_Z


title: TRI_1500_Ovary_48hp_C_Phase3_Y_Z


title: TRI_1500_Ovary_96h_B_Phase3_Y_Z


title: TRI_1500_Ovary_48hp_D_Phase3_Y_Z


title: TRI_300_Ovary_48hp_C_Phase3_Y_Z


title: TRI_1500_Ovary_48hp_B_Phase3_Y_Z


title: TRI_300_Ovary_48hp_B_Phase3_Y_Z


title: TRI_Control_Ovary_48hp_B_Phase3_Y_Z


title: TRI_Control_Ovary_48hp_C_Phase3_Y_Z


title: TRI_Control_Ovary_48hp_D_Phase3_Y_Z


title: TRI_Control_Ovary_48hp_A_Phase3_Y_Z


title: TRI_1500_Ovary_48h_C_Phase3_Y_Z


title: TRI_1500_Ovary_48h_D_Phase3_Y_Z


title: TRI_300_Ovary_48h_B_Phase3_Y_Z


title: TRI_300_Ovary_48h_A_Phase3_Y_Z


title: TRI_1500_Ovary_96h_C_Phase3_Y_Z


title: TRI_300_Ovary_48hp_D_Phase3_Y_Z


title: TRI_1500_Ovary_48hp_A_Phase3_Y_Z


title: TRI_Control_Ovary_48h_B_Phase3_Y_Z


title: TRI_300_Ovary_48h_C_Phase3_Y_Z


title: TRI_Control_Ovary_48h_A_Phase3_Y_Z


title: TRI_1500_Ovary_48h_B_Phase3_Y_Z


title: TRI_300_Ovary_48h_D_Phase3_Y_Z


title: TRI_300_Ovary_24hp_C_Phase3_Y_Z


title: TRI_300_Ovary_24hp_A_Phase3_Y_Z


title: TRI_300_Ovary_24hp_D_Phase3_Y_Z


title: TRI_1500_Ovary_48h_A_Phase3_Y_Z


title: TRI_1500_Ovary_24hp_A_Phase3_Y_Z


title: TRI_300_Ovary_24hp_B_Phase3_Y_Z


title: TRI_Control_Ovary_48h_C_Phase3_Y_Z


title: TRI_Control_Ovary_24hp_C_Phase3_Y_Z


title: TRI_Control_Ovary_24hp_B_Phase3_Y_Z


title: TRI_300_Ovary_24h_B_Phase3_Y_Z


title: TRI_300_Ovary_24h_D_Phase3_Y_Z


title: TRI_300_Ovary_24h_A_Phase3_Y_Z


title: TRI_300_Ovary_24h_C_Phase3_Y_Z


title: TRI_1500_Ovary_24hp_B_Phase3_Y_Z


title: TRI_1500_Ovary_24hp_D_Phase3_Y_Z


title: TRI_1500_Ovary_24hp_C_Phase3_Y_Z


title: TRI_Control_Ovary_24h_B_Phase3_Y_Z


title: TRI_1500_Ovary_24h_A_Phase3_Y_Z


title: TRI_1500_Ovary_24h_B_Phase3_Y_Z


title: TRI_300_Ovary_192hp_D_Phase3_Y_Z


title: TRI_Control_Ovary_24h_A_Phase3_Y_Z


title: TRI_Control_Ovary_24hp_A_Phase3_Y_Z


title: TRI_1500_Ovary_24h_D_Phase3_Y_Z


title: TRI_1500_Ovary_24h_C_Phase3_Y_Z


title: TRI_Control_Ovary_24h_E_Phase3_Y_Z


title: TRI_Control_Ovary_24h_D_Phase3_Y_Z


title: TRI_300_Ovary_192hp_B_Phase3_Y_Z


title: TRI_Control_Ovary_24hp_D_Phase3_Y_Z


title: TRI_1500_Ovary_192hp_B_Phase3_Y_Z


title: TRI_1500_Ovary_192hp_C_Phase3_Y_Z


title: TRI_Control_Ovary_192hp_C_Phase3_Y_Z


title: TRI_300_Ovary_192hp_C_Phase3_Y_Z


title: TRI_1500_Ovary_192hp_D_Phase3_Y_Z


title: TRI_Control_Ovary_24h_C_Phase3_Y_Z


title: TRI_Control_Ovary_192hp_D_Phase3_Y_Z


title: TRI_1500_Ovary_192hp_A_Phase3_Y_Z


title: TRI_Control_Ovary_192hp_B_Phase3_Y_Z


title: TRI_300_Ovary_192h_A_Phase3_Y_Z


title: TRI_300_Ovary_192h_D_Phase3_Y_Z


title: TRI_300_Ovary_192h_C_Phase3_Y_Z


title: TRI_1500_Ovary_192h_D_Phase3_Y_Z


title: TRI_Control_Ovary_192hp_A_Phase3_Y_Z


title: TRI_300_Ovary_192hp_A_Phase3_Y_Z


title: TRI_Control_Ovary_192h_D_Phase3_Y_Z


title: TRI_1500_Ovary_192h_C_Phase3_Y_Z


title: TRI_1500_Ovary_192h_B_Phase3_Y_Z


title: TRI_Control_Ovary_192h_B_Phase3_Y_Z


title: TRI_1500_Ovary_192h_A_Phase3_Y_Z


title: TRI_Control_Ovary_192h_C_Phase3_Y_Z


title: TRI_300_Ovary_192h_B_Phase3_Y_Z


title: TRI_Control_Ovary_ACT8h_D_X_Y_Z


title: TRI_Control_Ovary_ACT8h_B_X_Y_Z


title: TRI_1740_Ovary_ACT8h_D_X_Y_Z


title: TRI_1740_Ovary_ACT8h_C_X_Y_Z


title: TRI_Control_Ovary_ACT8h_C_X_Y_Z


title: TRI_1740_Ovary_ACT8h_A_X_Y_Z


title: TRI_Control_Ovary_ACT8h_A_X_Y_Z


title: TRI_1740_Ovary_ACT4h_B_X_Y_Z


title: TRI_1740_Ovary_ACT4h_C_X_Y_Z


title: TRI_Control_Ovary_192h_A_Phase3_Y_Z


title: TRI_1740_Ovary_ACT4h_D_X_Y_Z


title: TRI_Control_Ovary_ACT4h_D_X_Y_Z


title: TRI_1740_Ovary_ACT4h_A_X_Y_Z


title: TRI_1740_Ovary_ACT8h_B_X_Y_Z


title: TRI_Control_Ovary_ACT4h_A_X_Y_Z


title: TRI_Control_Ovary_ACT4h_B_X_Y_Z


title: TRI_1740_Ovary_ACT2h_B_X_Y_Z


title: TRI_Control_Ovary_ACT4h_C_X_Y_Z


title: TRI_1740_Ovary_ACT2h_D_X_Y_Z


title: TRI_1740_Ovary_ACT2h_A_X_Y_Z


title: TRI_1740_Ovary_ACT1h_C_X_Y_Z


title: TRI_Control_Ovary_ACT2h_C_X_Y_Z


title: TRI_1740_Ovary_ACT1h_B_X_Y_Z


title: TRI_Control_Ovary_ACT2h_A_X_Y_Z


title: TRI_Control_Ovary_ACT1h_D_X_Y_Z


title: TRI_1740_Ovary_ACT12h_D_X_Y_Z


title: TRI_Control_Ovary_ACT1h_C_X_Y_Z


title: TRI_1740_Ovary_ACT1h_A_X_Y_Z


title: TRI_Control_Ovary_ACT1h_B_X_Y_Z


title: TRI_Control_Ovary_ACT2h_D_X_Y_Z


title: TRI_1740_Ovary_ACT12h_B_X_Y_Z


title: TRI_1740_Ovary_ACT2h_C_X_Y_Z


title: TRI_Control_Ovary_ACT1h_A_X_Y_Z


title: TRI_Control_Ovary_ACT2h_B_X_Y_Z


title: TRI_1740_Ovary_ACT12h_A_X_Y_Z


title: TRI_1740_Ovary_ACT1h_D_X_Y_Z


title: TRI_Control_Ovary_ACT12h_C_X_Y_Z


title: TbTCCTCC_5_Ovary_21d_5_X_Y_Z

value: TBTCCTCC


title: TRI_Control_Ovary_ACT12h_D_X_Y_Z


title: TRI_Control_Ovary_ACT12h_B_X_Y_Z


title: TRI_1740_Ovary_ACT12h_C_X_Y_Z


title: TbTCCTCC_5_Ovary_21d_2_X_Y_Z


title: TbTCCTCC_5_Ovary_21d_1_X_Y_Z


title: TbTCCTCC_5_Ovary_21d_4_X_Y_Z


title: TbTCCTCC_1_Ovary_21d_5_X_Y_Z


title: TbTCCTCC_1_Ovary_21d_4_X_Y_Z


title: TbTCCTCC_5_Ovary_21d_3_X_Y_Z


title: TbTCCTCC_1_Ovary_21d_2_X_Y_Z


title: TbTCCTCC_1_Ovary_21d_1_X_Y_Z


title: TRI_Control_Ovary_ACT12h_A_X_Y_Z


title: TbTCCTBTCC_5_Ovary_21d_2_X_Y_Z

value: TBTCCTBTCC


title: TbTCCTBTCC_5_Ovary_21d_5_X_Y_Z


title: TbTCCTBTCC_5_Ovary_21d_4_X_Y_Z


title: TbTCCTBTCC_5_Ovary_21d_3_X_Y_Z


title: TbTCCTB_500_Ovary_21d_4_X_Y_Z

value: TBTCCTB

value: ng/L


title: TbTCC_Control_Ovary_21d_4_X_Y_Z

value: TBTCC


title: TbTCCTB_500_Ovary_21d_3_X_Y_Z


title: TbTCCTCC_1_Ovary_21d_3_X_Y_Z


title: TbTCC_Control_Ovary_21d_5_X_Y_Z


title: TbTCCTBTCC_5_Ovary_21d_1_X_Y_Z


title: TbTCC_Control_Ovary_21d_3_X_Y_Z


title: TbTCC_Control_Ovary_21d_1_X_Y_Z


title: TbEE2TB_500_Ovary_14d_1_X_Y_Z


title: TbEE2TbEE2_10_Ovary_14d_5_X_Y_Z


title: TbTCCTB_500_Ovary_21d_1_X_Y_Z


title: TbTCC_Control_Ovary_21d_2_X_Y_Z


title: TbTCCTB_500_Ovary_21d_2_X_Y_Z


title: TbEE2TB_500_Ovary_14d_4_X_Y_Z


title: TbEE2TB_500_Ovary_14d_3_X_Y_Z


title: TbEE2TB_500_Ovary_14d_2_X_Y_Z


title: TbEE2TB_500_Ovary_14d_5_X_Y_Z


title: TbEE2TbEE2_10_Ovary_14d_3_X_Y_Z


title: TbEE2TbEE2_10_Ovary_14d_4_X_Y_Z


title: TbEE2EE2_10_Ovary_14d_5_X_Y_Z


title: TbEE2TbEE2_1_Ovary_14d_2_X_Y_Z


title: TbEE2EE2_1_Ovary_14d_3_X_Y_Z


title: TbEE2TbEE2_10_Ovary_14d_1_X_Y_Z


title: TbEE2EE2_10_Ovary_14d_2_X_Y_Z


title: TbEE2EE2_1_Ovary_14d_1_X_Y_Z


title: TbEE2EE2_1_Ovary_14d_2_X_Y_Z


title: TbEE2EE2_10_Ovary_14d_4_X_Y_Z


title: TbEE2TbEE2_10_Ovary_14d_2_X_Y_Z


title: TbEE2EE2_1_Ovary_14d_4_X_Y_Z


title: TbEE2TbEE2_1_Ovary_14d_1_X_Y_Z


title: TbEE2TbEE2_1_Ovary_14d_5_X_Y_Z


title: TbEE2TbEE2_1_Ovary_14d_3_X_Y_Z


title: TbEE2TbEE2_1_Ovary_14d_4_X_Y_Z


title: TbEE2EE2_10_Ovary_14d_1_X_Y_Z


title: TbEE2_Control_Ovary_14d_2_X_Y_Z


title: TbEE2EE2_10_Ovary_14d_3_X_Y_Z


title: TbBPATbBPA_100_Ovary_14d_6_X_Y_Z

value: TBBPATBBPA


title: TbEE2_Control_Ovary_14d_3_X_Y_Z


title: TbEE2_Control_Ovary_14d_1_X_Y_Z


title: TbBPATbBPA_100_Ovary_14d_5_X_Y_Z


title: TbBPATB_500_Ovary_14d_5_X_Y_Z

value: TBBPATB


title: TbBPATB_500_Ovary_14d_2_X_Y_Z

value: OVARY


title: TbBPATB_500_Ovary_14d_4_X_Y_Z


title: TbBPATbBPA_100_Ovary_14d_3_X_Y_Z


title: TbBPATB_500_Ovary_14d_3_X_Y_Z


title: TbEE2_Control_Ovary_14d_4_X_Y_Z


title: TbBPATbBPA_100_Ovary_14d_2_X_Y_Z


title: TbBPATbBPA_100_Ovary_14d_4_X_Y_Z


title: TbBPATbBPA_10_Ovary_14d_1_X_Y_Z


title: TbBPATbBPA_10_Ovary_14d_3_X_Y_Z


title: TbBPABPA_100_Ovary_14d_5_X_Y_Z

value: TBBPABPA


title: TbBPATB_500_Ovary_14d_1_X_Y_Z


title: TbBPABPA_10_Ovary_14d_2_X_Y_Z


title: TbBPATbBPA_10_Ovary_14d_4_X_Y_Z


title: TbBPA_Control_Ovary_14d_1_X_Y_Z

value: TBBPA


title: TbBPATbBPA_10_Ovary_14d_2_X_Y_Z


title: TbBPATbBPA_100_Ovary_14d_1_X_Y_Z


title: TbBPABPA_100_Ovary_14d_2_X_Y_Z


title: TbBPABPA_10_Ovary_14d_3_X_Y_Z


title: TbBPA_Control_Ovary_14d_4_X_Y_Z


title: TB_30_Ovary_96hp_4_Phase3_Y_Z

value: TB


title: TbBPABPA_10_Ovary_14d_1_X_Y_Z


title: TB_500_Ovary_96hp_6_Phase3_Y_Z


title: TbBPABPA_100_Ovary_14d_4_X_Y_Z


title: TbBPABPA_100_Ovary_14d_1_X_Y_Z


title: TB_30_Ovary_96hp_3_Phase3_Y_Z


title: TB_500_Ovary_96hp_7_Phase3_Y_Z


title: TbBPA_Control_Ovary_14d_6_X_Y_Z


title: TbBPABPA_10_Ovary_14d_4_X_Y_Z


title: TB_30_Ovary_96hp_2_Phase3_Y_Z


title: TB_500_Ovary_96hp_2_Phase3_Y_Z


title: TB_Control_Ovary_96hp_2_Phase3_Y_Z


title: TB_500_Ovary_96hp_4_Phase3_Y_Z


title: TB_Control_Ovary_96hp_3_Phase3_Y_Z


title: TB_30_Ovary_96h_4_Phase3_Y_Z


title: TB_30_Ovary_96h_3_Phase3_Y_Z


title: TB_500_Ovary_96hp_3_Phase3_Y_Z


title: TbBPA_Control_Ovary_14d_2_X_Y_Z


title: TB_500_Ovary_96hp_5_Phase3_Y_Z


title: TbBPA_Control_Ovary_14d_5_X_Y_Z


title: TbBPABPA_100_Ovary_14d_3_X_Y_Z


title: TB_30_Ovary_96hp_5_Phase3_Y_Z


title: TB_Control_Ovary_96hp_5_Phase3_Y_Z


title: TB_30_Ovary_96h_6_Phase3_Y_Z


title: TB_30_Ovary_96h_7_Phase3_Y_Z


title: TB_Control_Ovary_96hp_6_Phase3_Y_Z


title: TB_500_Ovary_96h_2_Phase3_Y_Z


title: TB_Control_Ovary_96hp_7_Phase3_Y_Z


title: TB_500_Ovary_96h_6_Phase3_Y_Z


title: TB_Control_Ovary_96h_5_Phase3_Y_Z


title: TB_500_Ovary_48hp_5_Phase3_Y_Z


title: TB_500_Ovary_96h_3_Phase3_Y_Z


title: TB_Control_Ovary_96h_6_Phase3_Y_Z


title: TB_30_Ovary_96h_8_Phase3_Y_Z


title: TB_30_Ovary_96h_1_Phase3_Y_Z


title: TbBPA_Control_Ovary_14d_3_X_Y_Z


title: TB_Control_Ovary_96h_4_Phase3_Y_Z


title: TB_30_Ovary_48hp_3_Phase3_Y_Z


title: TB_Control_Ovary_96h_2_Phase3_Y_Z


title: TB_30_Ovary_48hp_2_Phase3_Y_Z


title: TB_500_Ovary_48hp_6_Phase3_Y_Z


title: TB_Control_Ovary_96h_1_Phase3_Y_Z


title: TB_500_Ovary_96h_5_Phase3_Y_Z


title: TB_500_Ovary_96h_4_Phase3_Y_Z


title: TB_30_Ovary_48hp_1_Phase3_Y_Z


title: TB_Control_Ovary_96hp_4_Phase3_Y_Z


title: TB_500_Ovary_48hp_1_Phase3_Y_Z


title: TB_500_Ovary_48hp_2_Phase3_Y_Z


title: TB_Control_Ovary_96h_3_Phase3_Y_Z


title: TB_500_Ovary_48hp_3_Phase3_Y_Z


title: TB_30_Ovary_96h_5_Phase3_Y_Z


title: TB_500_Ovary_48hp_7_Phase3_Y_Z


title: TB_Control_Ovary_48hp_6_Phase3_Y_Z


title: TB_Control_Ovary_48hp_4_Phase3_Y_Z


title: TB_Control_Ovary_48hp_5_Phase3_Y_Z


title: TB_30_Ovary_96h_2_Phase3_Y_Z


title: TB_500_Ovary_96hp_1_Phase3_Y_Z


title: TB_500_Ovary_96h_1_Phase3_Y_Z


title: TB_Control_Ovary_96hp_1_Phase3_Y_Z


title: TB_30_Ovary_48hp_4_Phase3_Y_Z


title: TB_30_Ovary_96hp_1_Phase3_Y_Z


title: TB_500_Ovary_48hp_4_Phase3_Y_Z


title: TB_500_Ovary_48h_3_Phase3_Y_Z


title: TB_30_Ovary_48h_2_Phase3_Y_Z


title: TB_30_Ovary_48h_8_Phase3_Y_Z


title: TB_30_Ovary_48h_1_Phase3_Y_Z


title: TB_500_Ovary_48h_8_Phase3_Y_Z


title: TB_30_Ovary_48h_7_Phase3_Y_Z


title: TB_30_Ovary_48h_6_Phase3_Y_Z


title: TB_30_Ovary_48h_5_Phase3_Y_Z


title: TB_500_Ovary_48h_7_Phase3_Y_Z


title: TB_500_Ovary_48h_6_Phase3_Y_Z


title: TB_30_Ovary_48h_3_Phase3_Y_Z


title: TB_Control_Ovary_48hp_2_Phase3_Y_Z


title: TB_500_Ovary_48h_1_Phase3_Y_Z


title: TB_Control_Ovary_48hp_1_Phase3_Y_Z


title: TB_500_Ovary_48h_4_Phase3_Y_Z


title: TB_Control_Ovary_48hp_3_Phase3_Y_Z


title: TB_500_Ovary_48h_5_Phase3_Y_Z


title: TB_30_Ovary_48h_4_Phase3_Y_Z


title: TB_Control_Ovary_48h_8_Phase3_Y_Z


title: TB_Control_Ovary_48h_6_Phase3_Y_Z


title: TB_Control_Ovary_48h_7_Phase3_Y_Z


title: TB_Control_Ovary_48h_4_Phase3_Y_Z


title: TB_500_Ovary_48h_2_Phase3_Y_Z


title: TB_Control_Ovary_48h_2_Phase3_Y_Z


title: TB_Control_Ovary_48h_3_Phase3_Y_Z


title: TB_30_Ovary_24hp_7_Phase3_Y_Z


title: TB_500_Ovary_24hp_6_Phase3_Y_Z


title: TB_30_Ovary_24hp_5_Phase3_Y_Z


title: TB_30_Ovary_24hp_2_Phase3_Y_Z


title: TB_Control_Ovary_48h_1_Phase3_Y_Z


title: TB_Control_Ovary_24hp_7_Phase3_Y_Z


title: TB_30_Ovary_24hp_3_Phase3_Y_Z


title: TB_500_Ovary_24hp_1_Phase3_Y_Z


title: TB_Control_Ovary_24hp_1_Phase3_Y_Z


title: TB_30_Ovary_24hp_1_Phase3_Y_Z


title: TB_30_Ovary_24hp_4_Phase3_Y_Z


title: TB_500_Ovary_24hp_2_Phase3_Y_Z


title: TB_30_Ovary_24hp_6_Phase3_Y_Z


title: TB_500_Ovary_24hp_5_Phase3_Y_Z


title: TB_500_Ovary_24hp_4_Phase3_Y_Z


title: TB_Control_Ovary_24hp_2_Phase3_Y_Z


title: TB_Control_Ovary_24hp_5_Phase3_Y_Z


title: TB_500_Ovary_24hp_3_Phase3_Y_Z


title: TB_Control_Ovary_24hp_3_Phase3_Y_Z


title: TB_30_Ovary_24h_8_Phase3_Y_Z


title: TB_Control_Ovary_24hp_6_Phase3_Y_Z


title: TB_Control_Ovary_24hp_4_Phase3_Y_Z


title: TB_Control_Ovary_48h_5_Phase3_Y_Z


title: TB_30_Ovary_24h_7_Phase3_Y_Z


title: TB_30_Ovary_24h_6_Phase3_Y_Z


title: TB_30_Ovary_24h_5_Phase3_Y_Z


title: TB_30_Ovary_24h_3_Phase3_Y_Z


title: TB_500_Ovary_24h_6_Phase3_Y_Z


title: TB_500_Ovary_24h_7_Phase3_Y_Z


title: TB_Control_Ovary_24h_6_Phase3_Y_Z


title: TB_500_Ovary_24h_2_Phase3_Y_Z


title: TB_30_Ovary_192hp_1_Phase3_Y_Z


title: TB_Control_Ovary_24h_2_Phase3_Y_Z


title: TB_30_Ovary_24h_4_Phase3_Y_Z


title: TB_30_Ovary_24h_1_Phase3_Y_Z


title: TB_30_Ovary_192hp_2_Phase3_Y_Z


title: TB_Control_Ovary_24h_7_Phase3_Y_Z


title: TB_30_Ovary_24h_2_Phase3_Y_Z


title: TB_500_Ovary_192hp_4_Phase3_Y_Z


title: TB_500_Ovary_24h_3_Phase3_Y_Z


title: TB_Control_Ovary_24h_5_Phase3_Y_Z


title: TB_500_Ovary_192hp_2_Phase3_Y_Z


title: TB_500_Ovary_24h_5_Phase3_Y_Z


title: TB_500_Ovary_24h_1_Phase3_Y_Z


title: TB_Control_Ovary_24h_1_Phase3_Y_Z


title: TB_500_Ovary_24h_4_Phase3_Y_Z


title: TB_500_Ovary_24h_8_Phase3_Y_Z


title: TB_Control_Ovary_192hp_5_Phase3_Y_Z


title: TB_500_Ovary_192hp_3_Phase3_Y_Z


title: TB_500_Ovary_192hp_1_Phase3_Y_Z


title: TB_Control_Ovary_24h_3_Phase3_Y_Z


title: TB_Control_Ovary_24h_4_Phase3_Y_Z


title: TB_Control_Ovary_192hp_1_Phase3_Y_Z


title: TB_30_Ovary_192h_7_Phase3_Y_Z


title: TB_Control_Ovary_192hp_3_Phase3_Y_Z


title: TB_Control_Ovary_192hp_4_Phase3_Y_Z


title: TB_Control_Ovary_192hp_2_Phase3_Y_Z


title: TB_30_Ovary_192h_5_Phase3_Y_Z


title: TB_500_Ovary_192h_5_Phase3_Y_Z


title: TB_30_Ovary_192h_1_Phase3_Y_Z


title: TB_30_Ovary_192h_2_Phase3_Y_Z


title: TB_Control_Ovary_192h_8_Phase3_Y_Z


title: TB_500_Ovary_192h_4_Phase3_Y_Z


title: TB_Control_Ovary_192h_5_Phase3_Y_Z


title: TB_30_Ovary_192h_6_Phase3_Y_Z


title: TB_500_Ovary_192h_7_Phase3_Y_Z


title: TB_500_Ovary_192h_8_Phase3_Y_Z


title: TB_500_Ovary_192h_1_Phase3_Y_Z


title: TB_Control_Ovary_192h_7_Phase3_Y_Z


title: TB_500_Ovary_192h_6_Phase3_Y_Z


title: TB_Control_Ovary_192h_3_Phase3_Y_Z


title: TB_30_Ovary_192h_3_Phase3_Y_Z


title: TB_Control_Ovary_192h_4_Phase3_Y_Z


title: TB_Control_Ovary_192h_6_Phase3_Y_Z


title: TB_Control_Ovary_192h_2_Phase3_Y_Z


title: TB_30_Ovary_192h_4_Phase3_Y_Z


title: TB_500_Ovary_192h_2_Phase3_Y_Z


title: RDX_Control_Ovary_21d_4_05mgL_Y_Z

value: RDX

value: mg/L


title: RDX_Control_Ovary_21d_1_05mgL_Y_Z


title: RDX_Control_Ovary_21d_2_05mgL_Y_Z


title: RDX_Control_Ovary_21d_3_05mgL_Y_Z


title: TB_500_Ovary_192h_3_Phase3_Y_Z


title: RDX_5_Ovary_21d_4_05mgL_Y_Z


title: RDX_5_Ovary_21d_1_05mgL_Y_Z


title: RDX_3_Ovary_21d_4_05mgL_Y_Z


title: RDX_0.7_Ovary_21d_1_05mgL_Y_Z


title: RDX_5_Ovary_21d_3_05mgL_Y_Z


title: PRO_22_Ovary_96hp_G_Phase3_Y_Z

value: PRO


title: RDX_0.7_Ovary_21d_4_05mgL_Y_Z


title: RDX_3_Ovary_21d_2_05mgL_Y_Z


title: TB_Control_Ovary_192h_1_Phase3_Y_Z


title: PRO_22_Ovary_96hp_B_Phase3_Y_Z

value: ug/L


title: RDX_0.01_Ovary_21d_3_05mgL_Y_Z


title: RDX_5_Ovary_21d_2_05mgL_Y_Z


title: PRO_22_Ovary_96hp_C_Phase3_Y_Z


title: RDX_0.7_Ovary_21d_3_05mgL_Y_Z


title: RDX_0.7_Ovary_21d_2_05mgL_Y_Z


title: RDX_0.1_Ovary_21d_3_05mgL_Y_Z


title: PRO_22_Ovary_96hp_E_Phase3_Y_Z


title: RDX_0.01_Ovary_21d_1_05mgL_Y_Z


title: RDX_3_Ovary_21d_3_05mgL_Y_Z


title: PRO_22_Ovary_96hp_F_Phase3_Y_Z


title: RDX_3_Ovary_21d_1_05mgL_Y_Z


title: PRO_300_Ovary_96hp_G_Phase3_Y_Z


title: PRO_300_Ovary_96hp_E_Phase3_Y_Z


title: RDX_0.1_Ovary_21d_1_05mgL_Y_Z


title: RDX_0.1_Ovary_21d_2_05mgL_Y_Z


title: PRO_22_Ovary_96hp_D_Phase3_Y_Z


title: PRO_300_Ovary_96hp_F_Phase3_Y_Z


title: PRO_300_Ovary_96hp_D_Phase3_Y_Z


title: RDX_0.01_Ovary_21d_2_05mgL_Y_Z


title: PRO_22_Ovary_96hp_A_Phase3_Y_Z


title: PRO_300_Ovary_96hp_C_Phase3_Y_Z


title: PRO_300_Ovary_96hp_B_Phase3_Y_Z


title: PRO_300_Ovary_96hp_A_Phase3_Y_Z


title: PRO_Control_Ovary_96hp_F_Phase3_Y_Z

value: CONTROL


title: PRO_300_Ovary_96h_A_Phase3_Y_Z


title: PRO_Control_Ovary_96hp_D_Phase3_Y_Z


title: PRO_22_Ovary_96h_C_Phase3_Y_Z


title: PRO_Control_Ovary_96hp_E_Phase3_Y_Z


title: PRO_Control_Ovary_96hp_B_Phase3_Y_Z


title: PRO_22_Ovary_96h_B_Phase3_Y_Z


title: PRO_300_Ovary_96h_B_Phase3_Y_Z


title: PRO_22_Ovary_96h_A_Phase3_Y_Z


title: PRO_300_Ovary_96h_G_Phase3_Y_Z


title: PRO_Control_Ovary_96hp_G_Phase3_Y_Z


title: PRO_300_Ovary_96h_E_Phase3_Y_Z


title: PRO_22_Ovary_96h_G_Phase3_Y_Z


title: PRO_Control_Ovary_96h_F_Phase3_Y_Z


title: PRO_22_Ovary_96h_E_Phase3_Y_Z


title: PRO_300_Ovary_96h_C_Phase3_Y_Z


title: PRO_Control_Ovary_96hp_C_Phase3_Y_Z


title: PRO_Control_Ovary_96hp_A_Phase3_Y_Z


title: PRO_Control_Ovary_96h_D_Phase3_Y_Z


title: PRO_Control_Ovary_96h_G_Phase3_Y_Z


title: PRO_22_Ovary_96h_F_Phase3_Y_Z


title: PRO_Control_Ovary_96h_E_Phase3_Y_Z


title: PRO_Control_Ovary_96h_C_Phase3_Y_Z


title: PRO_300_Ovary_96h_F_Phase3_Y_Z


title: PRO_22_Ovary_96h_D_Phase3_Y_Z


title: PRO_Control_Ovary_96h_B_Phase3_Y_Z


title: PRO_Control_Ovary_96h_A_Phase3_Y_Z


title: PRO_22_Ovary_48hp_F_Phase3_Y_Z


title: PRO_22_Ovary_48hp_B_Phase3_Y_Z


title: PRO_300_Ovary_48hp_B_Phase3_Y_Z


title: PRO_300_Ovary_48hp_C_Phase3_Y_Z


title: PRO_300_Ovary_48hp_F_Phase3_Y_Z


title: PRO_22_Ovary_48hp_D_Phase3_Y_Z


title: PRO_300_Ovary_48hp_G_Phase3_Y_Z


title: PRO_300_Ovary_48hp_D_Phase3_Y_Z


title: PRO_Control_Ovary_48hp_C_Phase3_Y_Z


title: PRO_Control_Ovary_48hp_A_Phase3_Y_Z


title: PRO_22_Ovary_48h_G_Phase3_Y_Z


title: PRO_300_Ovary_48hp_A_Phase3_Y_Z


title: PRO_Control_Ovary_48hp_G_Phase3_Y_Z


title: PRO_22_Ovary_48hp_G_Phase3_Y_Z


title: PRO_Control_Ovary_48hp_B_Phase3_Y_Z


title: PRO_Control_Ovary_48hp_F_Phase3_Y_Z


title: PRO_300_Ovary_48hp_E_Phase3_Y_Z


title: PRO_22_Ovary_48h_F_Phase3_Y_Z


title: PRO_22_Ovary_48hp_C_Phase3_Y_Z


title: PRO_Control_Ovary_48hp_E_Phase3_Y_Z


title: PRO_22_Ovary_48hp_E_Phase3_Y_Z


title: PRO_22_Ovary_48h_C_Phase3_Y_Z


title: PRO_22_Ovary_48h_E_Phase3_Y_Z


title: PRO_22_Ovary_48h_B_Phase3_Y_Z


title: PRO_22_Ovary_48hp_A_Phase3_Y_Z


title: PRO_22_Ovary_48h_A_Phase3_Y_Z


title: PRO_22_Ovary_48h_D_Phase3_Y_Z


title: PRO_Control_Ovary_48hp_D_Phase3_Y_Z


title: PRO_300_Ovary_48h_G_Phase3_Y_Z


title: PRO_300_Ovary_96h_D_Phase3_Y_Z


title: PRO_Control_Ovary_48h_C_Phase3_Y_Z


title: PRO_300_Ovary_48h_C_Phase3_Y_Z


title: PRO_Control_Ovary_48h_A_Phase3_Y_Z


title: PRO_22_Ovary_24hp_F_Phase3_Y_Z


title: PRO_Control_Ovary_48h_D_Phase3_Y_Z


title: PRO_300_Ovary_48h_F_Phase3_Y_Z


title: PRO_300_Ovary_48h_D_Phase3_Y_Z


title: PRO_Control_Ovary_48h_G_Phase3_Y_Z


title: PRO_300_Ovary_48h_A_Phase3_Y_Z


title: PRO_Control_Ovary_48h_B_Phase3_Y_Z


title: PRO_300_Ovary_48h_B_Phase3_Y_Z


title: PRO_22_Ovary_24hp_G_Phase3_Y_Z


title: PRO_300_Ovary_24hp_F_Phase3_Y_Z


title: PRO_300_Ovary_24hp_G_Phase3_Y_Z


title: PRO_22_Ovary_24hp_C_Phase3_Y_Z


title: PRO_22_Ovary_24hp_B_Phase3_Y_Z


title: PRO_300_Ovary_24hp_A_Phase3_Y_Z


title: PRO_Control_Ovary_48h_F_Phase3_Y_Z


title: PRO_22_Ovary_24hp_D_Phase3_Y_Z


title: PRO_Control_Ovary_24hp_F_Phase3_Y_Z


title: PRO_300_Ovary_24hp_D_Phase3_Y_Z


title: PRO_300_Ovary_24hp_B_Phase3_Y_Z


title: PRO_300_Ovary_48h_E_Phase3_Y_Z


title: PRO_300_Ovary_24hp_E_Phase3_Y_Z


title: PRO_Control_Ovary_48h_E_Phase3_Y_Z


title: PRO_300_Ovary_24hp_C_Phase3_Y_Z


title: PRO_22_Ovary_24hp_E_Phase3_Y_Z


title: PRO_22_Ovary_24hp_A_Phase3_Y_Z


title: PRO_Control_Ovary_24hp_E_Phase3_Y_Z


title: PRO_Control_Ovary_24hp_G_Phase3_Y_Z


title: PRO_Control_Ovary_24hp_A_Phase3_Y_Z


title: PRO_22_Ovary_24h_F_Phase3_Y_Z


title: PRO_Control_Ovary_24hp_D_Phase3_Y_Z


title: PRO_Control_Ovary_24hp_C_Phase3_Y_Z


title: PRO_22_Ovary_24h_C_Phase3_Y_Z


title: PRO_300_Ovary_24h_E_Phase3_Y_Z


title: PRO_300_Ovary_24h_F_Phase3_Y_Z


title: PRO_Control_Ovary_24hp_B_Phase3_Y_Z


title: PRO_22_Ovary_24h_A_Phase3_Y_Z


title: PRO_22_Ovary_24h_E_Phase3_Y_Z


title: PRO_300_Ovary_24h_D_Phase3_Y_Z


title: PRO_22_Ovary_24h_D_Phase3_Y_Z


title: PRO_22_Ovary_24h_B_Phase3_Y_Z


title: PRO_22_Ovary_192hp_G_Phase3_Y_Z


title: PRO_300_Ovary_24h_C_Phase3_Y_Z


title: PRO_300_Ovary_24h_B_Phase3_Y_Z


title: PRO_Control_Ovary_24h_D_Phase3_Y_Z


title: PRO_Control_Ovary_24h_C_Phase3_Y_Z


title: PRO_Control_Ovary_24h_E_Phase3_Y_Z


title: PRO_300_Ovary_24h_A_Phase3_Y_Z


title: PRO_22_Ovary_192hp_F_Phase3_Y_Z


title: PRO_Control_Ovary_24h_B_Phase3_Y_Z


title: PRO_Control_Ovary_24h_G_Phase3_Y_Z


title: PRO_22_Ovary_192hp_D_Phase3_Y_Z


title: PRO_Control_Ovary_24h_F_Phase3_Y_Z


title: PRO_22_Ovary_192hp_E_Phase3_Y_Z


title: PRO_22_Ovary_192hp_C_Phase3_Y_Z


title: PRO_22_Ovary_192hp_B_Phase3_Y_Z


title: PRO_22_Ovary_192hp_A_Phase3_Y_Z


title: PRO_Control_Ovary_24h_A_Phase3_Y_Z


title: PRO_300_Ovary_192hp_G_Phase3_Y_Z


title: PRO_300_Ovary_192hp_D_Phase3_Y_Z


title: PRO_Control_Ovary_192hp_F_Phase3_Y_Z


title: PRO_300_Ovary_192hp_B_Phase3_Y_Z


title: PRO_300_Ovary_192hp_E_Phase3_Y_Z


title: PRO_Control_Ovary_192hp_G_Phase3_Y_Z


title: PRO_300_Ovary_192hp_A_Phase3_Y_Z


title: PRO_Control_Ovary_192hp_D_Phase3_Y_Z


title: PRO_Control_Ovary_192hp_A_Phase3_Y_Z


title: PRO_22_Ovary_192h_G_Phase3_Y_Z


title: PRO_300_Ovary_192hp_C_Phase3_Y_Z


title: PRO_Control_Ovary_192hp_B_Phase3_Y_Z


title: PRO_22_Ovary_192h_F_Phase3_Y_Z


title: PRO_22_Ovary_192h_A_Phase3_Y_Z


title: PRO_22_Ovary_192h_D_Phase3_Y_Z


title: PRO_22_Ovary_192h_C_Phase3_Y_Z


title: PRO_22_Ovary_192h_E_Phase3_Y_Z


title: PRO_22_Ovary_192h_B_Phase3_Y_Z


title: PRO_300_Ovary_192h_F_Phase3_Y_Z


title: PRO_300_Ovary_192h_D_Phase3_Y_Z


title: PRO_300_Ovary_192h_B_Phase3_Y_Z


title: PRO_300_Ovary_192h_A_Phase3_Y_Z


title: PRO_300_Ovary_192h_E_Phase3_Y_Z


title: PRO_300_Ovary_192h_C_Phase3_Y_Z


title: PRO_300_Ovary_192h_G_Phase3_Y_Z


title: PRO_Control_Ovary_192hp_C_Phase3_Y_Z


title: PRO_Control_Ovary_192h_E_Phase3_Y_Z


title: PRO_Control_Ovary_192h_D_Phase3_Y_Z


title: PRO_Control_Ovary_192h_F_Phase3_Y_Z


title: PRO_Control_Ovary_192h_C_Phase3_Y_Z


title: PRO_200_Ovary_24h6h_3_X_Y_Z

value: 251959710005_Prochloraz in vivo FHM S0.1RE_0001


title: PRO_Control_Ovary_192h_A_Phase3_Y_Z


title: PRO_200_Ovary_24h6h_2_X_Y_Z

value: 251959710004_Prochloraz in vivo FHM S0.1RE_0001


title: PRO_Control_Ovary_24h6h_4_X_Y_Z


title: PRO_200_Ovary_24h6h_1_X_Y_Z

value: 251959710003_Prochloraz in vivo FHM S0.1RE_0001


title: PRO_Control_Ovary_192h_B_Phase3_Y_Z


title: PRO_Control_Ovary_24h6h_3_X_Y_Z


title: PRO_200_Ovary_24h6h_4_X_Y_Z


title: PRO_200_Ovary_24h24h_1_X_Y_Z


title: PRO_Control_Ovary_24h24h_3_X_Y_Z


title: PRO_Control_Ovary_24h6h_1_X_Y_Z


title: PRO_200_Ovary_24h24h_2_X_Y_Z


title: PRO_200_Ovary_24h12h_3_X_Y_Z


title: PRO_200_Ovary_24h24h_3_X_Y_Z


title: PRO_Control_Ovary_24h24h_4_X_Y_Z


title: PRO_200_Ovary_24h12h_4_X_Y_Z


title: PRO_Control_Ovary_24h24h_1_X_Y_Z


title: PRO_Control_Ovary_24h24h_2_X_Y_Z


title: PRO_Control_Ovary_24h6h_2_X_Y_Z


title: PRO_Control_Ovary_24h12h_4_X_Y_Z


title: PRO_200_Ovary_24h12h_2_X_Y_Z


title: PRO_200_Ovary_24h12h_1_X_Y_Z


title: Ovary_Stages_VTG-7

source_name: ovarian vitellogenic stage


title: PRO_Control_Ovary_24h12h_2_X_Y_Z


title: PRO_Control_Ovary_24h12h_3_X_Y_Z


title: Ovary_Stages_VTG-3


title: Ovary_Stages_VTG-2


title: Ovary_Stages_VTG-5


title: Ovary_Stages_PV-6

source_name: ovarian pre-vitellogenic stage


title: Ovary_Stages_VTG-4


title: Ovary_Stages_OE-3

source_name: ovarian ovulated eggs stage


title: Ovary_Stages_VTG-6


title: Ovary_Stages_PV-4


title: Ovary_Stages_OE-1


title: Ovary_Stages_AT-5

source_name: ovarian atretic stage


title: Ovary_Stages_VTG-1


title: Ovary_Stages_OE-2


title: PRO_Control_Ovary_192h_G_Phase3_Y_Z


title: Ovary_Stages_AT-6


title: Ovary_Stages_MO-3

source_name: ovarian mature ovary stage


title: Ovary_Stages_PV-2


title: Ovary_Stages_PV-5


title: Ovary_Stages_MO-4


title: Ovary_Stages_PV-1


title: PRO_Control_Ovary_24h12h_1_X_Y_Z


title: Ovary_Stages_MO-2


title: Ovary_Stages_PV-3


title: Ovary_Stages_AT-7


title: Ovary_Stages_MO-5


title: Ovary_Stages_MO-6


title: Ovary_Stages_MO-1


title: Ovary_Stages_AT-1


title: Ovary_Stages_AT-4


title: KTCTNTTNT_4.4_Ovary_024h6h_4_X_Y_Z

value: KTCTNTTNT

value: uM


title: KTCTNTTNT_4.4_Ovary_024h6h_2_X_Y_Z


title: Ovary_Stages_OE-4


title: KTCTNT_Control_Ovary_024h6h_3_X_Y_Z

value: KTCTNT


title: KTCTNTKTC_0.5_Ovary_024h6h_2_X_Y_Z

value: KTCTNTKTC


title: KTCTNTTNT_4.4_Ovary_024h4h_3_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h6h_3_X_Y_Z


title: KTCTNT_Control_Ovary_024h6h_4_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h4h_4_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h6h_1_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h4h_2_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h4h_1_X_Y_Z


title: Ovary_Stages_AT-2


title: KTCTNTKTC_0.5_Ovary_024h6h_3_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h4h_4_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h4h_1_X_Y_Z


title: KTCTNT_Control_Ovary_024h4h_3_X_Y_Z


title: KTCTNT_Control_Ovary_024h4h_4_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h6h_1_X_Y_Z


title: Ovary_Stages_AT-3


title: KTCTNTKTC_0.5_Ovary_024h4h_3_X_Y_Z


title: KTCTNT_Control_Ovary_024h6h_2_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h4h_2_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h6h_4_X_Y_Z


title: KTCTNT_Control_Ovary_024h6h_1_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h30m_3_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h2h_4_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h2h_1_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h30m_1_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h2h_3_X_Y_Z


title: KTCTNT_Control_Ovary_024h30m_2_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h30m_4_X_Y_Z


title: KTCTNT_Control_Ovary_024h30m_4_X_Y_Z


title: KTCTNT_Control_Ovary_024h30m_1_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h30m_3_X_Y_Z


title: KTCTNT_Control_Ovary_024h4h_1_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h30m_2_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h30m_1_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h2h_3_X_Y_Z


title: KTCTNT_Control_Ovary_024h2h_3_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h2h_2_X_Y_Z


title: KTCTNT_Control_Ovary_024h2h_2_X_Y_Z


title: KTCTNT_Control_Ovary_024h2h_4_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h30m_4_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h24h_4_X_Y_Z


title: KTCTNT_Control_Ovary_024h4h_2_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h2h_4_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h2h_1_X_Y_Z


title: KTCTNT_Control_Ovary_024h30m_3_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h30m_2_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h24h_3_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h24h_2_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h2h_2_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h24h_1_X_Y_Z


title: KTCTNT_Control_Ovary_024h24h_2_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h1h_4_X_Y_Z


title: KTCTNT_Control_Ovary_024h24h_3_X_Y_Z


title: KTCTNT_Control_Ovary_024h24h_4_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h24h_1_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h1h_2_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h24h_3_X_Y_Z


title: KTCTNT_Control_Ovary_024h24h_1_X_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h24h_2_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h1h_3_X_Y_Z


title: KTCTNT_Control_Ovary_024h1h_3_X_Y_Z


title: KTC_40_Ovary_96h_5_Phase3_Y_Z

value: KTC


title: KTCTNTKTC_0.5_Ovary_024h1h_3_X_Y_Z

value: OVARY


title: KTCTNT_Control_Ovary_024h2h_1_X_Y_Z


title: KTCTNT_Control_Ovary_024h1h_4_X_Y_Z


title: KTC_400_Ovary_96h_1_Phase3_Y_Z


title: KTC_400_Ovary_96h_2_Phase3_Y_Z


title: KTC_400_Ovary_96h_5_Phase3_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h1h_1_X_Y_Z


title: KTC_400_Ovary_96h_3_Phase3_Y_Z


title: KTCTNT_Control_Ovary_024h1h_1_X_Y_Z


title: KTCTNT_Control_Ovary_024h1h_2_X_Y_Z


title: KTC_400_Ovary_96h_4_Phase3_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h1h_2_X_Y_Z


title: KTC_40_Ovary_96h_4_Phase3_Y_Z


title: KTCTNTKTC_0.5_Ovary_024h24h_4_X_Y_Z


title: KTCTNTTNT_4.4_Ovary_024h1h_4_X_Y_Z


title: KTC_40_Ovary_96h_2_Phase3_Y_Z


title: KTC_40_Ovary_96h_1_Phase3_Y_Z


title: KTC_Control_Ovary_96h_5_Phase3_Y_Z


title: KTC_400_Ovary_8d_3_Phase3_Y_Z


title: KTC_Control_Ovary_96h_1_Phase3_Y_Z


title: KTC_400_Ovary_8d_1_Phase3_Y_Z


title: KTC_40_Ovary_96h_3_Phase3_Y_Z


title: KTC_Control_Ovary_96h_4_Phase3_Y_Z


title: KTC_400_Ovary_8d_4_Phase3_Y_Z


title: KTC_Control_Ovary_96h_2_Phase3_Y_Z


title: KTC_40_Ovary_8d_4_Phase3_Y_Z


title: KTC_Control_Ovary_8d_5_Phase3_Y_Z


title: KTC_400_Ovary_8d_2_Phase3_Y_Z


title: KTC_400_Ovary_8d8dp_4_Phase3_Y_Z


title: KTC_40_Ovary_8d_5_Phase3_Y_Z


title: KTC_Control_Ovary_8d_4_Phase3_Y_Z


title: KTC_40_Ovary_8d_1_Phase3_Y_Z


title: KTC_40_Ovary_8d_3_Phase3_Y_Z


title: KTC_Control_Ovary_96h_3_Phase3_Y_Z


title: KTC_40_Ovary_8d8dp_5_Phase3_Y_Z


title: KTC_400_Ovary_8d8dp_3_Phase3_Y_Z


title: KTC_40_Ovary_8d8dp_4_Phase3_Y_Z


title: KTC_400_Ovary_8d8dp_2_Phase3_Y_Z


title: KTC_Control_Ovary_8d_1_Phase3_Y_Z


title: KTC_400_Ovary_8d8dp_5_Phase3_Y_Z


title: KTC_Control_Ovary_8d_3_Phase3_Y_Z


title: KTC_40_Ovary_8d_2_Phase3_Y_Z


title: KTC_40_Ovary_8d8dp_3_Phase3_Y_Z


title: KTC_Control_Ovary_8d_2_Phase3_Y_Z


title: KTC_40_Ovary_8d8dp_2_Phase3_Y_Z


title: KTC_400_Ovary_8d8dp_1_Phase3_Y_Z


title: KTC_40_Ovary_8d8dp_1_Phase3_Y_Z


title: KTC_Control_Ovary_8d8dp_4_Phase3_Y_Z


title: KTC_Control_Ovary_8d8dp_5_Phase3_Y_Z


title: KTC_Control_Ovary_8d8dp_3_Phase3_Y_Z


title: KTC_Control_Ovary_8d8dp_1_Phase3_Y_Z


title: KTC_400_Ovary_8d1dp_1_Phase3_Y_Z


title: KTC_400_Ovary_8d1dp_5_Phase3_Y_Z


title: KTC_400_Ovary_8d1dp_2_Phase3_Y_Z


title: KTC_40_Ovary_8d1dp_5_Phase3_Y_Z


title: KTC_400_Ovary_8d1dp_4_Phase3_Y_Z


title: KTC_40_Ovary_8d1dp_2_Phase3_Y_Z


title: KTC_40_Ovary_8d1dp_3_Phase3_Y_Z


title: KTC_Control_Ovary_8d8dp_2_Phase3_Y_Z


title: KTC_40_Ovary_8d1dp_1_Phase3_Y_Z


title: KTC_Control_Ovary_8d1dp_5_Phase3_Y_Z


title: KTC_400_Ovary_8d1dp_3_Phase3_Y_Z


title: KTC_Control_Ovary_8d1dp_3_Phase3_Y_Z


title: KTC_Control_Ovary_8d1dp_1_Phase3_Y_Z


title: KTC_Control_Ovary_8d1dp_4_Phase3_Y_Z


title: KTC_Control_Ovary_8d1dp_2_Phase3_Y_Z


title: KTC_40_Ovary_8d16dp_5_Phase3_Y_Z


title: KTC_400_Ovary_8d16dp_2_Phase3_Y_Z


title: KTC_400_Ovary_8d16dp_3_Phase3_Y_Z


title: KTC_40_Ovary_8d16dp_2_Phase3_Y_Z


title: KTC_40_Ovary_8d1dp_4_Phase3_Y_Z


title: KTC_400_Ovary_8d16dp_5_Phase3_Y_Z


title: KTC_Control_Ovary_8d16dp_1_Phase3_Y_Z


title: KTC_40_Ovary_8d16dp_4_Phase3_Y_Z


title: KTC_40_Ovary_8d16dp_3_Phase3_Y_Z


title: KTC_400_Ovary_8d16dp_1_Phase3_Y_Z


title: KTC_Control_Ovary_8d16dp_3_Phase3_Y_Z


title: KTC_400_Ovary_8d16dp_4_Phase3_Y_Z


title: KTC_Control_Ovary_8d16dp_2_Phase3_Y_Z


title: KTC_40_Ovary_8d16dp_1_Phase3_Y_Z


title: KTC_400_Ovary_4d1dp_3_Phase3_Y_Z


title: KTC_400_Ovary_4d1dp_4_Phase3_Y_Z


title: KTC_Control_Ovary_8d16dp_4_Phase3_Y_Z


title: KTC_40_Ovary_4d1dp_2_Phase3_Y_Z


title: KTC_400_Ovary_4d1dp_5_Phase3_Y_Z


title: KTC_40_Ovary_4d1dp_4_Phase3_Y_Z


title: KTC_40_Ovary_4d1dp_5_Phase3_Y_Z


title: KTC_40_Ovary_4d1dp_1_Phase3_Y_Z


title: KTC_40_Ovary_4d1dp_3_Phase3_Y_Z


title: KTC_400_Ovary_4d1dp_2_Phase3_Y_Z


title: KTC_Control_Ovary_4d1dp_5_Phase3_Y_Z


title: KTC_Control_Ovary_4d1dp_4_Phase3_Y_Z


title: KTC_400_Ovary_4d1dp_1_Phase3_Y_Z


title: KTC_400_Ovary_24h_5_Phase3_Y_Z


title: KTC_Control_Ovary_4d1dp_1_Phase3_Y_Z


title: KTC_Control_Ovary_4d1dp_3_Phase3_Y_Z


title: KTC_400_Ovary_24h_1_Phase3_Y_Z


title: KTC_400_Ovary_24h_2_Phase3_Y_Z


title: KTC_400_Ovary_24h_3_Phase3_Y_Z


title: KTC_400_Ovary_24h_4_Phase3_Y_Z


title: KTC_Control_Ovary_24h_5_Phase3_Y_Z


title: KTC_Control_Ovary_24h_4_Phase3_Y_Z


title: KTC_400_Ovary_1d1dp_5_Phase3_Y_Z


title: KTC_Control_Ovary_24h_3_Phase3_Y_Z


title: KTC_40_Ovary_24h_5_Phase3_Y_Z


title: KTC_40_Ovary_24h_4_Phase3_Y_Z


title: KTC_Control_Ovary_24h_2_Phase3_Y_Z


title: KTC_40_Ovary_24h_1_Phase3_Y_Z


title: KTC_40_Ovary_24h_3_Phase3_Y_Z


title: KTC_40_Ovary_24h_2_Phase3_Y_Z


title: KTC_Control_Ovary_4d1dp_2_Phase3_Y_Z


title: KTC_400_Ovary_1d1dp_1_Phase3_Y_Z


title: KTC_400_Ovary_1d1dp_4_Phase3_Y_Z


title: KTC_40_Ovary_1d1dp_5_Phase3_Y_Z


title: KTC_40_Ovary_1d1dp_2_Phase3_Y_Z


title: KTC_40_Ovary_1d1dp_4_Phase3_Y_Z


title: KTC_40_Ovary_1d1dp_3_Phase3_Y_Z


title: KTC_Control_Ovary_24h_1_Phase3_Y_Z


title: KTC_Control_Ovary_1d1dp_4_Phase3_Y_Z


title: KTC_400_Ovary_1d1dp_3_Phase3_Y_Z


title: KTC_150_Ovary_24h6h_3_X_Y_Z


title: KTC_400_Ovary_1d1dp_2_Phase3_Y_Z


title: KTC_150_Ovary_24h6h_1_X_Y_Z


title: KTC_40_Ovary_1d1dp_1_Phase3_Y_Z


title: KTC_150_Ovary_24h6h_2_X_Y_Z


title: KTC_Control_Ovary_1d1dp_5_Phase3_Y_Z


title: KTC_Control_Ovary_1d1dp_1_Phase3_Y_Z


title: KTC_150_Ovary_24h24h_3_X_Y_Z


title: KTC_150_Ovary_24h24h_2_X_Y_Z


title: KTC_150_Ovary_24h6h_4_X_Y_Z


title: KTC_Control_Ovary_24h6h_4_X_Y_Z


title: KTC_Control_Ovary_24h6h_1_X_Y_Z


title: KTC_150_Ovary_24h24h_4_X_Y_Z


title: KTC_Control_Ovary_24h6h_2_X_Y_Z


title: KTC_Control_Ovary_24h6h_3_X_Y_Z


title: KTC_150_Ovary_24h24h_1_X_Y_Z


title: KTC_Control_Ovary_1d1dp_3_Phase3_Y_Z


title: KTC_150_Ovary_24h12h_3_X_Y_Z


title: KTC_Control_Ovary_24h24h_4_X_Y_Z


title: KTC_Control_Ovary_24h24h_3_X_Y_Z


title: KTC_150_Ovary_24h12h_2_X_Y_Z


title: KTC_Control_Ovary_24h24h_1_X_Y_Z


title: KTC_Control_Ovary_24h24h_2_X_Y_Z


title: KTC_Control_Ovary_24h12h_4_X_Y_Z


title: KTC_Control_Ovary_24h12h_3_X_Y_Z


title: KTC_315_Ovary_012h8h_1_X_Y_Z


title: KTC_Control_Ovary_24h12h_2_X_Y_Z


title: KTC_315_Ovary_012h8h_4_X_Y_Z


title: KTC_Control_Ovary_012h8h_4_X_Y_Z


title: KTC_Control_Ovary_24h12h_1_X_Y_Z


title: KTC_150_Ovary_24h12h_4_X_Y_Z


title: KTC_315_Ovary_012h8h_2_X_Y_Z


title: KTC_Control_Ovary_012h8h_2_X_Y_Z


title: KTC_Control_Ovary_012h8h_3_X_Y_Z


title: KTC_315_Ovary_012h6h_1_X_Y_Z


title: KTC_315_Ovary_012h6h_2_X_Y_Z


title: KTC_150_Ovary_24h12h_1_X_Y_Z


title: KTC_Control_Ovary_012h6h_4_X_Y_Z


title: KTC_Control_Ovary_012h8h_1_X_Y_Z


title: KTC_Control_Ovary_012h6h_2_X_Y_Z


title: KTC_315_Ovary_012h4h_3_X_Y_Z


title: KTC_315_Ovary_012h6h_3_X_Y_Z


title: KTC_315_Ovary_012h4h_4_X_Y_Z


title: KTC_315_Ovary_012h8h_3_X_Y_Z


title: KTC_Control_Ovary_012h6h_1_X_Y_Z


title: KTC_315_Ovary_012h6h_4_X_Y_Z


title: KTC_315_Ovary_012h4h_1_X_Y_Z


title: KTC_Control_Ovary_012h4h_3_X_Y_Z


title: KTC_315_Ovary_012h4h_2_X_Y_Z


title: KTC_Control_Ovary_012h4h_1_X_Y_Z


title: KTC_Control_Ovary_012h4h_2_X_Y_Z


title: KTC_Control_Ovary_012h2h_3_X_Y_Z


title: KTC_315_Ovary_012h2h_2_X_Y_Z


title: KTC_315_Ovary_012h2h_3_X_Y_Z


title: KTC_Control_Ovary_012h2h_1_X_Y_Z


title: KTC_Control_Ovary_012h2h_2_X_Y_Z


title: KTC_Control_Ovary_012h2h_4_X_Y_Z


title: KTC_315_Ovary_012h2h_1_X_Y_Z


title: KTC_315_Ovary_012h1h_1_X_Y_Z


title: KTC_315_Ovary_012h1h_2_X_Y_Z


title: KTC_315_Ovary_012h1h_3_X_Y_Z


title: KTC_315_Ovary_012h1h_4_X_Y_Z


title: KTC_Control_Ovary_012h1h_3_X_Y_Z


title: KTC_Control_Ovary_012h1h_1_X_Y_Z


title: KTC_Control_Ovary_012h6h_3_X_Y_Z


title: KTC_Control_Ovary_012h4h_4_X_Y_Z


title: KTC_Control_Ovary_012h1h_4_X_Y_Z


title: KTC_Control_Ovary_012h1h_2_X_Y_Z


title: KTC_Control_Ovary_012h12h_4_X_Y_Z


title: KTC_315_Ovary_012h12h_2_X_Y_Z


title: KTC_315_Ovary_012h10h_4_X_Y_Z


title: KTC_315_Ovary_012h12h_3_X_Y_Z


title: KTC_315_Ovary_012h12h_4_X_Y_Z


title: KTC_Control_Ovary_012h12h_1_X_Y_Z


title: KTC_315_Ovary_012h12h_1_X_Y_Z


title: KTC_315_Ovary_012h10h_2_X_Y_Z


title: KTC_315_Ovary_012h10h_3_X_Y_Z


title: KTC_315_Ovary_012h10h_1_X_Y_Z


title: KTC_Control_Ovary_012h12h_3_X_Y_Z


title: KTC_Control_Ovary_012h12h_2_X_Y_Z


title: KTC_Control_Ovary_012h10h_4_X_Y_Z


title: KTC_Control_Ovary_012h10h_3_X_Y_Z


title: KTC_Control_Ovary_012h10h_1_X_Y_Z


title: GEM_600_Ovary_8d_6_X_Y_Z

value: GEM


title: GEM_600_Ovary_8d_5_X_Y_Z


title: GEM_600_Ovary_8d_4_X_Y_Z


title: GEM_600_Ovary_8d_3_X_Y_Z


title: GEM_15_Ovary_8d_5_X_Y_Z


title: GEM_600_Ovary_8d_1_X_Y_Z


title: GEM_15_Ovary_8d_3_X_Y_Z


title: GEM_15_Ovary_8d_2_X_Y_Z


title: GEM_15_Ovary_8d_4_X_Y_Z


title: GEM_15_Ovary_8d_1_X_Y_Z


title: GEM_Control_Ovary_8d_4_X_Y_Z


title: GEM_Control_Ovary_8d_5_X_Y_Z


title: KTC_Control_Ovary_012h10h_2_X_Y_Z


title: FLU_50_Ovary_96hp_B_Phase3_Y_Z

value: FLU


title: FLU_50_Ovary_96hp_A_Phase3_Y_Z


title: FLU_500_Ovary_96hp_D_Phase3_Y_Z


title: GEM_Control_Ovary_8d_2_X_Y_Z


title: FLU_500_Ovary_96hp_C_Phase3_Y_Z


title: GEM_Control_Ovary_8d_3_X_Y_Z


title: FLU_50_Ovary_96hp_D_Phase3_Y_Z


title: FLU_500_Ovary_96hp_B_Phase3_Y_Z


title: FLU_50_Ovary_96hp_E_Phase3_Y_Z

value: 251959710237_FHM sub-adult RDX challenge 070909 350PMT


title: GEM_600_Ovary_8d_2_X_Y_Z


title: FLU_50_Ovary_96hp_C_Phase3_Y_Z


title: FLU_Control_Ovary_96hp_A_Phase3_Y_Z


title: FLU_Control_Ovary_96hp_B_Phase3_Y_Z


title: FLU_Control_Ovary_96hp_E_Phase3_Y_Z

value: 251959710194_FHM sub-adult RDX challenge 070909 350PMT


title: KTC_Control_Ovary_1d1dp_2_Phase3_Y_Z


title: FLU_500_Ovary_96hp_A_Phase3_Y_Z


title: FLU_50_Ovary_96h_E_Phase3_Y_Z

value: 251959710193_FHM sub-adult RDX challenge 070909 350PMT


title: FLU_Control_Ovary_96hp_C_Phase3_Y_Z


title: FLU_50_Ovary_96h_F2_Phase3_Y_Z


title: GEM_Control_Ovary_8d_1_X_Y_Z


title: FLU_50_Ovary_96h_C_Phase3_Y_Z


title: FLU_50_Ovary_96h_D_Phase3_Y_Z


title: FLU_50_Ovary_96h_A_Phase3_Y_Z


title: FLU_50_Ovary_96h_B_Phase3_Y_Z


title: FLU_500_Ovary_96h_C_Phase3_Y_Z


title: FLU_500_Ovary_96h_B_Phase3_Y_Z


title: FLU_500_Ovary_96h_D_Phase3_Y_Z


title: FLU_Control_Ovary_96h_E_Phase3_Y_Z


title: FLU_500_Ovary_96h_A_Phase3_Y_Z


title: FLU_50_Ovary_48hp_D_Phase3_Y_Z


title: FLU_Control_Ovary_96h_C_Phase3_Y_Z


title: FLU_Control_Ovary_96h_D_Phase3_Y_Z


title: FLU_50_Ovary_48hp_C_Phase3_Y_Z


title: FLU_Control_Ovary_96h_B_Phase3_Y_Z


title: FLU_500_Ovary_48hp_A_Phase3_Y_Z


title: FLU_50_Ovary_48hp_B_Phase3_Y_Z


title: FLU_Control_Ovary_96h_A_Phase3_Y_Z


title: FLU_500_Ovary_48hp_B_Phase3_Y_Z


title: FLU_Control_Ovary_48hp_B_Phase3_Y_Z


title: FLU_50_Ovary_48h_D_Phase3_Y_Z


title: FLU_Control_Ovary_48hp_C_Phase3_Y_Z


title: FLU_500_Ovary_48hp_C_Phase3_Y_Z


title: FLU_50_Ovary_48hp_A_Phase3_Y_Z


title: FLU_50_Ovary_48h_C_Phase3_Y_Z


title: FLU_50_Ovary_48h_E_Phase3_Y_Z


title: FLU_Control_Ovary_48hp_E_Phase3_Y_Z


title: FLU_50_Ovary_48h_A_Phase3_Y_Z


title: FLU_50_Ovary_48h_B_Phase3_Y_Z


title: FLU_Control_Ovary_48hp_D_Phase3_Y_Z


title: FLU_Control_Ovary_48hp_A_Phase3_Y_Z


title: FLU_500_Ovary_48h_C_Phase3_Y_Z


title: FLU_500_Ovary_48h_B_Phase3_Y_Z


title: FLU_Control_Ovary_48h_D_Phase3_Y_Z


title: FLU_500_Ovary_48hp_D_Phase3_Y_Z


title: FLU_500_Ovary_48h_E_Phase3_Y_Z


title: FLU_500_Ovary_48h_A_Phase3_Y_Z


title: FLU_Control_Ovary_48h_C_Phase3_Y_Z


title: FLU_500_Ovary_48h_D_Phase3_Y_Z


title: FLU_50_Ovary_24hp_D_Phase3_Y_Z


title: FLU_Control_Ovary_48h_A_Phase3_Y_Z


title: FLU_50_Ovary_24hp_C_Phase3_Y_Z


title: FLU_50_Ovary_24hp_A_Phase3_Y_Z


title: FLU_Control_Ovary_48h_B_Phase3_Y_Z


title: FLU_500_Ovary_24hp_F_Phase3_Y_Z


title: FLU_500_Ovary_24hp_E_Phase3_Y_Z


title: FLU_Control_Ovary_24hp_B_Phase3_Y_Z


title: FLU_50_Ovary_24hp_B_Phase3_Y_Z


title: FLU_Control_Ovary_24hp_D_Phase3_Y_Z


title: FLU_500_Ovary_24hp_C_Phase3_Y_Z


title: FLU_500_Ovary_24hp_B_Phase3_Y_Z


title: FLU_500_Ovary_24hp_D_Phase3_Y_Z


title: FLU_Control_Ovary_24hp_A_Phase3_Y_Z


title: LOC400043-silenced cells using siRNA #2, biological rep1 [HuGene-1_0-st]

city: Copenhagen SV

first: Shizuka

last: Uchida

email: heart.lncrna@gmail.com, suc@dcm.aau.dk

address: Frederikskaj 10B, 2. (building C)

department: Department of Clinical Medicine

country: Denmark

institute: Aalborg University

hyb_protocol: Following fragmentation, cRNA were hybridized, washed and stained in the Affymetrix Fluidics Station 400 according to the standard Affymetrix protocol.

scan_protocol: GeneChips were scanned according to the standard Affymetrix protocol.

data_processing: The data were analyzed using noncoder web interface (http://noncoder.mpi-bn.mpg.de). After the normalization by Robust Multi-array Average (RMA) and the application of moderate t-statistics via the limma package, Transcript Cluster IDs that do not match to a gene or to multiple genes were discarded. Then, a standard deviation is calculated across samples. For a gene that matches to multiple Transcript Cluster IDs, the Transcript Cluster ID with the highest standard deviation was kept for further analysis.

label: biotin

source_name: HEK-293 cells, LOC400043 siRNA

label_protocol: Biotinylated cRNA were prepared according to the standard Affymetrix protocol.

growth_protocol: HEK-293 cells were cultured in the growth medium containing 10% FBS (Life Technologies, #10270106) in DMEM with low glucose, pyruvate (Life Technologies, #31885-023) supplemented with antibiotics (penicillin and streptomycin, Sigma-Aldrich, #P4333). All cells were cultured at 37°C in a humidified atmosphere containing 5% CO2.

extract_protocol: Trizol extraction of total RNA was performed according to the manufacturer's instruction.

treatment_protocol: Transient siRNA transfection (10nM final concentration) was carried out using RNAiMax (Life Technologies) according to the manufacturer's protocol.

tag: sirna


title: LINC00324-silenced cells using siRNA #2, biological rep1 [HuGene-1_0-st]

source_name: HEK-293 cells, LINC00324 siRNA


title: LOC400043-silenced cells using siRNA #2, biological rep2 [HuGene-1_0-st]


title: LINC00324-silenced cells using siRNA #1, biological rep2 [HuGene-1_0-st]


title: FLU_50_Ovary_24h_E_Phase3_Y_Z


title: FLU_Control_Ovary_24hp_C_Phase3_Y_Z


title: FLU_50_Ovary_24h_B_Phase3_Y_Z


title: FLU_50_Ovary_24h_D_Phase3_Y_Z


title: FLU_500_Ovary_24h_E_Phase3_Y_Z


title: FLU_50_Ovary_24h_A_Phase3_Y_Z


title: FLU_500_Ovary_24hp_A_Phase3_Y_Z


title: LINC00324-silenced cells using siRNA #1, biological rep1 [HuGene-1_0-st]


title: siScramble-transfected cells, biological rep2 [HuGene-1_0-st]

source_name: HEK-293 cells, siScramble

value: Scramble


title: LOC400043-silenced cells using siRNA #1, biological rep2 [HuGene-1_0-st]


title: siScramble-transfected cells, biological rep1 [HuGene-1_0-st]


title: FLU_50_Ovary_24h_C_Phase3_Y_Z

value: ug/L


title: LINC00324-silenced cells using siRNA #2, biological rep2 [HuGene-1_0-st]


title: FLU_500_Ovary_24h_D_Phase3_Y_Z


title: LOC400043-silenced cells using siRNA #1, biological rep1 [HuGene-1_0-st]


title: FLU_500_Ovary_24h_C_Phase3_Y_Z


title: FLU_500_Ovary_24h_B_Phase3_Y_Z


title: CV36

city: London

first: Clare

last: Isacke

address: 237 Fulham Road

department: Breast Cancer Now

country: United Kingdom

institute: Institute of Cancer Research

description: Tumour endothelial cels isolated from Endosialin knockout tumours replicate 4

hyb_protocol: Standard Illumina hybridization protocol

scan_protocol: Standard Illumina scanning protocol

data_processing: Illumina raw data were extracted using the GenomeStudio software and were transformed and normalised using variance-stabilising transformation and robust spline normalisation method in the Lumi package in R

organism: Mus musculus

source_name: 67NR primary tumour xenograft

label_protocol: Total RNA was amplified using the Ovation Pico WTA System V2 (Nugen Technologies). Total RNA was converted into cDNA, and amplified by In Vitro Transcription (IVT) to generate biotin-labelled cRNA. 1.6 µg of cRNA was hybridised to the MouseWG-6 v2.0 Expression BeadChip (Illumina) according to the manufacturer’s Direct Hybridisation Assay protocol

growth_protocol: 5 x 10^5 tumour cells were inoculated orthotopically into the 4th mammary fat pad of Ub-GFP Balb/c mice. Tumours were left to grow for 2-4 weeks, until they reached an average diameter of 10 mm. Total RNA was isolated from freshly FACSorted cells from primary tumour single cell suspensions (without in vitro growth).

extract_protocol: Total RNA was extracted with QIAGEN RNeasy mini kit in accordance with the prescribed protocol provided with the kit. Quality control was performed with Agilent Bioanalyser

tag: strain

value: Balb/c UbGFP

tag: sample type

value: 67NR xenograft

value: primary tumour

tag: Sex

value: female

tag: age

value: 6-8 weeks


title: FLU_500_Ovary_24h_A_Phase3_Y_Z

tag: chemical

tag: dose


title: CV31

description: Tumour endothelial cels isolated from Endosialin knockout tumours replicate 1

tag: tissue


title: CV33

description: Tumour endothelial cels isolated from Endosialin knockout tumours replicate 2


title: FLU_Control_Ovary_24h_D_Phase3_Y_Z

value: CONTROL

tag: exposure duration

tag: dosage unit


title: FLU_Control_Ovary_24h_C_Phase3_Y_Z

tag: age (month)

tag: arrayname


title: CV35

description: Tumour endothelial cels isolated from Endosialin knockout tumours replicate 3


title: CV28

description: Tumour endothelial cels isolated from Endosialin wild type tumours replicate 4


title: FLU_50_Ovary_192hp_D_Phase3_Y_Z

tag: featureextractiontime


title: FLU_Control_Ovary_24h_B_Phase3_Y_Z


title: FLU_Control_Ovary_24h_A_Phase3_Y_Z


title: CV27

description: Tumour endothelial cels isolated from Endosialin wild type tumours replicate 3


title: CV25

description: Tumour endothelial cels isolated from Endosialin wild type tumours replicate 1


title: CV15

description: Tumour pericytes isolated from Endosialin wild type tumours replicate 4


title: CV23

description: Tumour pericytes isolated from Endosialin knockout tumours replicate 4


title: FLU_50_Ovary_192hp_B_Phase3_Y_Z


title: FLU_Control_Ovary_24h_E_Phase3_Y_Z


title: FLU_50_Ovary_192hp_A_Phase3_Y_Z


title: CV14

description: Tumour pericytes isolated from Endosialin wild type tumours replicate 3


title: FLU_50_Ovary_192hp_C_Phase3_Y_Z


title: FLU_500_Ovary_192hp_E_Phase3_Y_Z


title: CV20

description: Tumour pericytes isolated from Endosialin knockout tumours replicate 2


title: CV13

description: Tumour pericytes isolated from Endosialin wild type tumours replicate 2


title: CV26

description: Tumour endothelial cels isolated from Endosialin wild type tumours replicate 2


title: CV18

description: Tumour pericytes isolated from Endosialin knockout tumours replicate 1


title: CV12

description: Tumour pericytes isolated from Endosialin wild type tumours replicate 1


title: FLU_500_Ovary_192hp_B_Phase3_Y_Z


title: FLU_Control_Ovary_96hp_D_Phase3_Y_Z


title: FLU_500_Ovary_192hp_C_Phase3_Y_Z


title: CV22

description: Tumour pericytes isolated from Endosialin knockout tumours replicate 3


title: FLU_Control_Ovary_192hp_D_Phase3_Y_Z

description:
chemical abbreviations: BPA, bisphenol-A; EE2, 17a-ethynyl estradiol;  FAD, fadrozole; FLU, flutamide; GEM, Gemfibrozil; KTC, ketoconazole; PRO, prochloraz; RDX, hexahydro-1,3,5-trinitro-1,3,5-triazine; TB, 17 -trenbolone; TCC, triclocarban; TNT, 2,4,6-trinitrotoluene; TRI,trilostane; VIN, vinclozolin; WLSSD, effluent from Western Lake Superior Sanitary District
Exposure duration abbreviations: D, day; H, hour; M, minute; HP, hours post exposure ; DP, days post exposure ; ACT, acute
Naming convention for sample names with multiple chemicals: Relative to the corresponding controls, additional chemcials present in a treated sample indicate its exposure conditions.  For example, compared to KTCTNT_Control_Ovary_024h1h_1_X_Y_Z, the treated sample KTCTNTKTC_0.5_Ovary_024h1h_1_X_Y_Z was exposed to the chemical KTC.  Similarly, with TbBPA_Control_Ovary_14d_1_X_Y_Z indicating a control sample, the sample TbBPATbBPA_10_Ovary_14d_1_X_Y_Z was exposed to both Tb and BPA.


title: FLU_500_Ovary_192hp_A_Phase3_Y_Z


title: FLU_50_Ovary_192h_D_Phase3_Y_Z


title: FLU_50_Ovary_192h_C_Phase3_Y_Z


title: FLU_500_Ovary_192hp_D_Phase3_Y_Z


title: FLU_Control_Ovary_192hp_B_Phase3_Y_Z


title: FLU_500_Ovary_192h_B_Phase3_Y_Z


title: FLU_50_Ovary_192h_B_Phase3_Y_Z


title: FLU_Control_Ovary_192h_E_Phase3_Y_Z


title: FLU_500_Ovary_192h_C_Phase3_Y_Z


title: FLU_Control_Ovary_192hp_A_Phase3_Y_Z


title: FLU_Control_Ovary_192h_C_Phase3_Y_Z


title: Patient 345

city: South San Francisco

first: Richard

last: Bourgon

state: CA

address: 1 DNA Way, MS 93

department: Bioinformatics & Computational Biology

institute: Genentech, Inc.

hyb_protocol: Per NanoString Total RNA Standard Protocol for formalin-fixed, paraffin-embedded (FFPE) samples.

data_processing: Raw count data were logged (base 2). A synthetic target distribution was computed by averaging expression across all samples for each gene. Raw log-scale expression values for each sample were centered and scaled so as to have the same mean and standard deviation as endogenous (i.e., non-control and non-housekeeping) probes in the synthetic target distribution. Finally, normalized log-expression values were converted to z-score so that each gene had mean 0 and standard deviation 1 across the panel. Note that this conversion took place before 27 outlier samples were dropped; data presented here no longer have row-wise means and SDs of exactly 0 and 1, respectively. See NanoStringQCPro package on Bioconductor for processing of supporting raw count RCC and platform definition RLF files.

label: Nucleotide/fluorophore barcode

source_name: Microdissected FFPE tumor sample, newly diagnosed supratentorial glioblastoma

tag: idh1 status

value: Mutant

tag: phillips subtype

value: Proneural

tag: tcga subtype

tag: treatment

value: Bevacizumab

tag: surgical status

value: Female

tag: corticosteroids

value: On

tag: kps

tag: mgmt status

value: Methylated

tag: mmse

tag: rpa class

tag: who

tag: os time to event (months)

tag: os event type (0 = censored)

tag: pfs time to event (months)

tag: pfs event type (0 = censored)


title: FLU_Control_Ovary_192h_D_Phase3_Y_Z

tag: chemical

value: FLU

tag: dose

tag: tissue

value: OVARY

tag: exposure duration

tag: dosage unit

tag: age (month)

tag: arrayname


title: FLU_Control_Ovary_192h_B_Phase3_Y_Z

tag: featureextractiontime


title: FLU_500_Ovary_192h_D_Phase3_Y_Z


title: FLU_500_Ovary_192h_A_Phase3_Y_Z


title: FLU_Control_Ovary_192h_F_Phase3_Y_Z

value: 251959710194_FHM sub-adult RDX challenge 070909 350PMT


title: FLU_500_Ovary_112h8h_3_X_Y_Z


title: FLU_500_Ovary_112h8h_4_X_Y_Z


title: FLU_50_Ovary_192h_A_Phase3_Y_Z


title: FLU_Control_Ovary_192h_A_Phase3_Y_Z


title: Patient 333

scan_protocol: Per NanoString Total RNA Standard Protocol for formalin-fixed, paraffin-embedded (FFPE) samples.

tag: idh1 status

tag: phillips subtype

tag: tcga subtype

tag: treatment

value: Placebo

tag: surgical status

tag: Sex

value: Male

tag: age

tag: corticosteroids

value: Off

tag: kps

value: Non-methylated


title: FLU_Control_Ovary_112h8h_4_X_Y_Z

tag: chemical

value: ug/L


title: FLU_500_Ovary_112h8h_1_X_Y_Z

tag: dose


title: FLU_Control_Ovary_112h8h_3_X_Y_Z

tag: tissue


title: FLU_Control_Ovary_112h8h_2_X_Y_Z

tag: exposure duration


title: FLU_Control_Ovary_112h8h_1_X_Y_Z

tag: dosage unit


title: C142 stress

city: Montreal

first: Moshe

last: Szyf

state: Quebec

address: McIntyre Medical Building, 3655 Promenade Sir William Osler, Room 1309

department: Pharmacology

country: Canada

institute: McGill University

hyb_protocol: All the steps of hybridization, washing, scanning and feature extraction were performed following the Agilent protocols for chip-on-chip analysis (MeDIP).

scan_protocol: Scanning was performed using the Agilent Technologies Scanner G2505B. Probe intensities were extracted from scanned microarray images using Agilent's Feature Extraction 10.7.3.1 Image Analysis Software

data_processing: The extracted intensities were then analyzed using the R software environment for statistical computing (R Development Core Team, 2007) (http://www.r-project.org/). Log-ratios of the bound (Cy5) and input (Cy3) microarray channel intensities were computed for each microarray.  Microarray quality was assessed using plots generated by the feature extraction software in addition to correlation matrix visualizations. Microarrays were normalized using quantile-normalization 8. Estimates of DNA methylation levels based on microarray probe intensities were obtained using a Bayesian deconvolution algorithm. Differential methylation between groups was determined in two stages. The first stage used linear models implemented in the ‘limma’ package 10 of Bioconductor 11 to compute a modified t-statistic at the individual probe level. As in typical microarray studies, the number of sample profiles is small so there is little information per probe from which to estimate probe variance. Hence, the modified t-statistic for each probe makes use of variance estimates derived from the other probes on the microarray. Correlation between technical replicates was modeled as a random effect using the “block” variable. An individual probe was called differentially methylated if the significance of its t-statistic was at most 0.05 (uncorrected for multiple testing) and the associated difference of log-normalized means between the groups was at least 0.5. In the second stage, differential statistics per promoter were derived from the t-statistics of the probes within the promoter. In particular, the Wilcoxon rank-sum test was used to identify enrichment for probes within the promoter having large positive or large negative t-statistics. The resulting promoter p-values were adjusted for multiple testing by calculating false discovery rates using the Benjamini-Hochberg algorithm. A promoter was called differentially methylated if its false discovery rate was at most 0.2 and it contained at least one probe called differentially methylated, as defined above.

organism: Rattus norvegicus

label_protocol: After the sonication step, methylated DNA was immunoprecipitated with 10 μg of anti-5methyl-cytosine antibody (Eurogentec, Fremont, CA, USA) that is specific to DNA methylation, does not recognize hydroxymethylated DNA, and reveals changes in 5-methyl-cytosine exclusively. The DNA antibody complex was immunoprecipitated with protein G, and the methylated DNA was re-suspended in 0.25 ml of digestion buffer (50 mM TRisHCl pH = 8; 10 mM EDTA; 0.5 % SDS) and treated with 40 μg of proteinase K overnight at 55°C. The input and bound fractions were phenol/chloroform-extracted and ethanol-precipitated The input and bound fractions were amplified using the Whole Genome Amplification Kit (Sigma-Aldrich; St. Luis; MO; USA) and then labeled for microarray hybridization with Cy3-dUTP and Cy5-dUTP, respectively, using the CGH Enzymatic Labeling Kit (Agilent Technologies; Mississauga; ON; Canada) in accordance with the manufacturer´s instructions.

growth_protocol: Nulliparous adult female (body weight 230–260 g) and male (400 g) Sprague-Dawley rats were purchased from a commercial breeder (Charles River, Calco, Italy). Upon arrival, they were pair-housed with a same-sex conspecific with food and water available ad libitum (21±1 °C, 60±10% relative humidity, regular 12/12 h light/dark cycle). After 10 days of habituation in the facility, rats were mated for 24 h and individually housed immediately thereafter. Pregnant females were randomly assigned to control (Ctrl) or prenatal stress (PNS) conditions. In particular, PNS consisted of restraining pregnant dams in a transparent Plexiglas cylinder (7.5 cm diameter, 19 cm length) under bright light for 45 min three times daily during the last week of gestation until delivery. PNS sessions were separated by 2–3 h intervals and conducted at varying periods of the day in order to reduce habituation. Control rats were left undisturbed. On postnatal day (PND) 1, pups from Ctrl and PNS dams were weighted, and litters were culled to 5 males and 5 females. Weaning occurred on PND21 and same sex rats were housed in groups of 3 per cage. At PND62 one male pertaining to each litter was sacrificed for microarray analysis.

extract_protocol: After decapitation, brain tissues were dissected, immediately frozen on dry ice and stored at -80°C for later analyses. Dissections were performed according to the atlas of Paxinos and Watson. In detail, the prefrontal cortex was dissected from 2-mm thick slices (prefrontal cortex defined as Cg1, Cg3, and IL sub-regions corresponding to the plates 6–9). Isolation of DNA and RNA from the same rat specimen was performed using the AllPrep DNA/RNA Mini kit (Qiagen, Milan, Italy), in accordance with the instructions of the manufacturer.

tag: gender

value: male

tag: protocol

value: prenatally stressed

tag: chip antibody

value: anti-5-methylcytidine (33D3) antibody (Eurogentec)

value: PFC

value: postnatal day 62


title: C182 control

value: control


title: C145 stress


title: C184 control


title: C185 control


title: C144 stress


title: FLU_Control_Ovary_112h4h_4_X_Y_Z

value: CONTROL

tag: age (month)

tag: arrayname

tag: featureextractiontime


title: FLU_Control_Ovary_112h4h_3_X_Y_Z


title: C141 stress


title: FLU_500_Ovary_112h2h_4_X_Y_Z


title: FLU_Control_Ovary_192hp_C_Phase3_Y_Z


title: FLU_500_Ovary_112h4h_4_X_Y_Z


title: C180 control


title: FLU_Control_Ovary_112h4h_2_X_Y_Z


title: FLU_500_Ovary_112h2h_2_X_Y_Z


title: FLU_500_Ovary_112h4h_1_X_Y_Z


title: FLU_500_Ovary_112h2h_1_X_Y_Z


title: FLU_500_Ovary_112h4h_3_X_Y_Z


title: FLU_500_Ovary_112h8h_2_X_Y_Z


title: FLU_Control_Ovary_112h2h_4_X_Y_Z


title: FLU_500_Ovary_112h4h_2_X_Y_Z


title: FLU_Control_Ovary_112h2h_2_X_Y_Z


title: FLU_500_Ovary_112h1h_4_X_Y_Z


title: FLU_Control_Ovary_112h1h_3_X_Y_Z


title: FLU_500_Ovary_112h1h_3_X_Y_Z


title: FLU_500_Ovary_112h2h_3_X_Y_Z


title: FLU_Control_Ovary_112h2h_1_X_Y_Z


title: FLU_Control_Ovary_112h1h_2_X_Y_Z


title: FLU_Control_Ovary_112h4h_1_X_Y_Z


title: FLU_Control_Ovary_112h1h_1_X_Y_Z


title: FLU_500_Ovary_112h12h_3_X_Y_Z


title: FLU_500_Ovary_112h12h_4_X_Y_Z


title: FLU_Control_Ovary_112h1h_4_X_Y_Z


title: FLU_500_Ovary_112h1h_2_X_Y_Z


title: FLU_500_Ovary_112h1h_1_X_Y_Z


title: FLU_Control_Ovary_112h2h_3_X_Y_Z


title: FLU_500_Ovary_112h12h_1_X_Y_Z


title: FAD_30_Ovary_96hp_5_Phase3_Y_Z

value: FAD


title: FAD_30_Ovary_96hp_4_Phase3_Y_Z


title: FLU_Control_Ovary_112h12h_2_X_Y_Z


title: FLU_500_Ovary_112h12h_2_X_Y_Z


title: FAD_30_Ovary_96hp_6_Phase3_Y_Z


title: FAD_30_Ovary_96hp_3_Phase3_Y_Z


title: FLU_Control_Ovary_112h12h_1_X_Y_Z


title: FAD_30_Ovary_96hp_2_Phase3_Y_Z


title: FAD_3_Ovary_96hp_7_Phase3_Y_Z


title: FAD_3_Ovary_96hp_6_Phase3_Y_Z


title: FLU_Control_Ovary_112h12h_3_X_Y_Z


title: FAD_3_Ovary_96hp_2_Phase3_Y_Z


title: FAD_30_Ovary_96hp_8_Phase3_Y_Z


title: FAD_30_Ovary_96hp_1_Phase3_Y_Z


title: Patient 285

label_protocol: Per NanoString Total RNA Standard Protocol for formalin-fixed, paraffin-embedded (FFPE) samples.

tag: idh1 status

value: Mutant

tag: phillips subtype

value: Proneural

tag: tcga subtype

tag: treatment

value: Female

value: On

tag: mgmt status

value: Methylated

tag: mmse

tag: rpa class

tag: who

tag: os time to event (months)

tag: os event type (0 = censored)

tag: pfs time to event (months)

tag: pfs event type (0 = censored)


title: FAD_3_Ovary_96hp_1_Phase3_Y_Z

tag: chemical

tag: dose

tag: tissue

value: OVARY

tag: exposure duration

tag: dosage unit


title: FAD_Control_Ovary_96hp_6_Phase3_Y_Z

tag: age (month)

tag: arrayname

tag: featureextractiontime


title: FAD_3_Ovary_96hp_5_Phase3_Y_Z


title: FAD_Control_Ovary_96hp_4_Phase3_Y_Z


title: FAD_30_Ovary_96hp_7_Phase3_Y_Z


title: FAD_Control_Ovary_96hp_2_Phase3_Y_Z


title: FAD_Control_Ovary_96hp_1_Phase3_Y_Z


title: FAD_3_Ovary_96hp_4_Phase3_Y_Z


title: FAD_Control_Ovary_96hp_5_Phase3_Y_Z


title: FAD_3_Ovary_96hp_3_Phase3_Y_Z


title: FAD_Control_Ovary_96hp_7_Phase3_Y_Z


title: FAD_30_Ovary_96h_7_Phase3_Y_Z


title: FAD_Control_Ovary_96hp_3_Phase3_Y_Z


title: FAD_30_Ovary_96h_3_Phase3_Y_Z


title: FAD_3_Ovary_96h_8_Phase3_Y_Z


title: FAD_30_Ovary_96h_1_Phase3_Y_Z


title: Patient 269

extract_protocol: Per NanoString Total RNA Standard Protocol for formalin-fixed, paraffin-embedded (FFPE) samples.

tag: idh1 status

tag: phillips subtype

value: Unclassified

tag: tcga subtype

tag: treatment

value: Bevacizumab

tag: surgical status

tag: Sex

value: Male

tag: age

tag: corticosteroids

value: Off

tag: kps

value: Missing


title: FAD_3_Ovary_96h_2_Phase3_Y_Z

tag: chemical

value: ug/L


title: FAD_Control_Ovary_96h_8_Phase3_Y_Z

tag: dose


title: FAD_30_Ovary_96h_4_Phase3_Y_Z

tag: tissue


title: FAD_3_Ovary_96h_4_Phase3_Y_Z

tag: exposure duration


title: FAD_Control_Ovary_96h_6_Phase3_Y_Z

tag: dosage unit


title: FAD_3_Ovary_96h_1_Phase3_Y_Z

tag: age (month)


title: FAD_3_Ovary_96h_5_Phase3_Y_Z

tag: arrayname


title: FAD_3_Ovary_96h_3_Phase3_Y_Z

tag: featureextractiontime


title: FAD_30_Ovary_96h_6_Phase3_Y_Z


title: FAD_30_Ovary_96h_5_Phase3_Y_Z


title: FAD_Control_Ovary_96h_1_Phase3_Y_Z


title: FAD_3_Ovary_96h_6_Phase3_Y_Z


title: FAD_30_Ovary_96h_2_Phase3_Y_Z


title: FAD_Control_Ovary_96h_7_Phase3_Y_Z


title: FAD_3_Ovary_96h_7_Phase3_Y_Z


title: FAD_Control_Ovary_96h_4_Phase3_Y_Z


title: FAD_Control_Ovary_96h_2_Phase3_Y_Z


title: FAD_30_Ovary_48hp_7_Phase3_Y_Z


title: FAD_30_Ovary_48hp_6_Phase3_Y_Z


title: FAD_Control_Ovary_96h_3_Phase3_Y_Z


title: FAD_30_Ovary_48hp_5_Phase3_Y_Z


title: FAD_30_Ovary_48hp_4_Phase3_Y_Z


title: FAD_30_Ovary_48hp_2_Phase3_Y_Z


title: FAD_Control_Ovary_96h_5_Phase3_Y_Z


title: FAD_30_Ovary_48hp_3_Phase3_Y_Z


title: Patient 227

tag: idh1 status

tag: mgmt status

tag: mmse

tag: rpa class

tag: who

tag: os time to event (months)

tag: os event type (0 = censored)

tag: pfs time to event (months)

tag: pfs event type (0 = censored)


title: FAD_3_Ovary_48hp_3_Phase3_Y_Z

tag: chemical


title: FAD_3_Ovary_48hp_7_Phase3_Y_Z

tag: dose


title: FAD_Control_Ovary_48hp_4_Phase3_Y_Z

tag: tissue


title: FAD_30_Ovary_48h_5_Phase3_Y_Z

tag: exposure duration


title: FAD_3_Ovary_48hp_6_Phase3_Y_Z

tag: dosage unit


title: FAD_3_Ovary_48hp_5_Phase3_Y_Z

tag: age (month)


title: FAD_30_Ovary_48h_7_Phase3_Y_Z

tag: arrayname


title: FAD_Control_Ovary_48hp_3_Phase3_Y_Z

tag: featureextractiontime


title: FAD_Control_Ovary_48hp_7_Phase3_Y_Z


title: FAD_30_Ovary_48hp_1_Phase3_Y_Z


title: FAD_3_Ovary_48hp_2_Phase3_Y_Z


title: FAD_Control_Ovary_48hp_8_Phase3_Y_Z


title: FAD_Control_Ovary_48hp_6_Phase3_Y_Z


title: FAD_3_Ovary_48hp_4_Phase3_Y_Z


title: FAD_30_Ovary_48h_6_Phase3_Y_Z


title: FAD_3_Ovary_48h_7_Phase3_Y_Z


title: FAD_Control_Ovary_48hp_2_Phase3_Y_Z


title: FAD_3_Ovary_48hp_1_Phase3_Y_Z


title: FAD_Control_Ovary_48hp_5_Phase3_Y_Z


title: FAD_3_Ovary_48hp_8_Phase3_Y_Z


title: FAD_30_Ovary_48h_4_Phase3_Y_Z


title: FAD_30_Ovary_48h_1_Phase3_Y_Z


title: FAD_30_Ovary_48h_3_Phase3_Y_Z


title: FAD_30_Ovary_48h_8_Phase3_Y_Z


title: FAD_3_Ovary_48h_8_Phase3_Y_Z


title: FAD_Control_Ovary_48hp_1_Phase3_Y_Z


title: FAD_30_Ovary_48h_2_Phase3_Y_Z


title: FAD_3_Ovary_48h_6_Phase3_Y_Z


title: FAD_3_Ovary_48h_5_Phase3_Y_Z


title: FAD_3_Ovary_48h_3_Phase3_Y_Z


title: FAD_3_Ovary_48h_4_Phase3_Y_Z


title: FAD_3_Ovary_48h_1_Phase3_Y_Z


title: FAD_Control_Ovary_48h_7_Phase3_Y_Z


title: FAD_Control_Ovary_48h_6_Phase3_Y_Z


title: FLU_Control_Ovary_112h12h_4_X_Y_Z

value: FLU


title: FAD_30_Ovary_24hp_7_Phase3_Y_Z


title: FAD_Control_Ovary_96hp_8_Phase3_Y_Z


title: FAD_Control_Ovary_48h_2_Phase3_Y_Z


title: FAD_30_Ovary_24hp_8_Phase3_Y_Z


title: FAD_Control_Ovary_48h_3_Phase3_Y_Z


title: FAD_Control_Ovary_48h_8_Phase3_Y_Z


title: FAD_30_Ovary_24hp_4_Phase3_Y_Z


title: FAD_3_Ovary_48h_2_Phase3_Y_Z


title: FAD_30_Ovary_24hp_3_Phase3_Y_Z


title: FAD_Control_Ovary_48h_1_Phase3_Y_Z


title: FAD_30_Ovary_24hp_6_Phase3_Y_Z


title: FAD_30_Ovary_24hp_2_Phase3_Y_Z


title: FAD_30_Ovary_24hp_1_Phase3_Y_Z


title: FAD_Control_Ovary_48h_5_Phase3_Y_Z


title: FAD_3_Ovary_24hp_8_Phase3_Y_Z


title: FAD_3_Ovary_24hp_3_Phase3_Y_Z


title: FAD_3_Ovary_24hp_7_Phase3_Y_Z


title: FAD_Control_Ovary_48h_4_Phase3_Y_Z


title: FAD_3_Ovary_24hp_4_Phase3_Y_Z


title: FAD_30_Ovary_24hp_5_Phase3_Y_Z


title: Patient 171

tag: idh1 status

tag: phillips subtype

tag: tcga subtype

tag: treatment

value: Placebo

tag: surgical status

tag: Sex

tag: age

tag: corticosteroids

tag: kps


title: FAD_3_Ovary_24hp_6_Phase3_Y_Z

tag: chemical


title: FAD_3_Ovary_24hp_5_Phase3_Y_Z

tag: dose


title: FAD_3_Ovary_24hp_1_Phase3_Y_Z

tag: tissue


title: FAD_30_Ovary_24h_2_Phase3_Y_Z

tag: exposure duration


title: FAD_Control_Ovary_24hp_2_Phase3_Y_Z

tag: dosage unit


title: FAD_30_Ovary_24h_6_Phase3_Y_Z

tag: age (month)


title: FAD_3_Ovary_24h_3_Phase3_Y_Z

tag: arrayname


title: FAD_Control_Ovary_24hp_6_Phase3_Y_Z

tag: featureextractiontime


title: FAD_3_Ovary_24h_7_Phase3_Y_Z


title: FAD_Control_Ovary_24hp_7_Phase3_Y_Z


title: FAD_Control_Ovary_24hp_5_Phase3_Y_Z


title: FAD_3_Ovary_24hp_2_Phase3_Y_Z


title: FAD_30_Ovary_24h_7_Phase3_Y_Z


title: FAD_Control_Ovary_24hp_3_Phase3_Y_Z


title: FAD_30_Ovary_24h_3_Phase3_Y_Z


title: FAD_3_Ovary_24h_8_Phase3_Y_Z


title: FAD_3_Ovary_24h_6_Phase3_Y_Z


title: FAD_3_Ovary_24h_4_Phase3_Y_Z


title: FAD_30_Ovary_24h_5_Phase3_Y_Z


title: FAD_3_Ovary_24h_5_Phase3_Y_Z


title: FAD_30_Ovary_24h_4_Phase3_Y_Z


title: FAD_Control_Ovary_24hp_8_Phase3_Y_Z


title: FAD_Control_Ovary_24hp_4_Phase3_Y_Z


title: FAD_30_Ovary_24h_1_Phase3_Y_Z


title: FAD_Control_Ovary_24h_5_Phase3_Y_Z


title: FAD_Control_Ovary_24hp_1_Phase3_Y_Z


title: FAD_3_Ovary_24h_1_Phase3_Y_Z


title: FAD_Control_Ovary_24h_4_Phase3_Y_Z


title: FAD_Control_Ovary_24h_2_Phase3_Y_Z


title: FAD_Control_Ovary_24h_3_Phase3_Y_Z


title: FAD_Control_Ovary_24h_1_Phase3_Y_Z


title: FAD_30_Ovary_192hp_2_Phase3_Y_Z


title: FAD_30_Ovary_192hp_3_Phase3_Y_Z


title: FAD_30_Ovary_192hp_5_Phase3_Y_Z


title: FAD_30_Ovary_192hp_1_Phase3_Y_Z


title: FAD_30_Ovary_192hp_7_Phase3_Y_Z


title: FAD_3_Ovary_192hp_3_Phase3_Y_Z


title: FAD_3_Ovary_192hp_6_Phase3_Y_Z


title: FAD_30_Ovary_192hp_4_Phase3_Y_Z


title: FAD_3_Ovary_192hp_2_Phase3_Y_Z


title: FAD_3_Ovary_192hp_4_Phase3_Y_Z


title: FAD_3_Ovary_192hp_7_Phase3_Y_Z


title: FAD_3_Ovary_192hp_8_Phase3_Y_Z


title: FAD_Control_Ovary_192hp_7_Phase3_Y_Z


title: FAD_30_Ovary_192h_6_Phase3_Y_Z


title: FAD_Control_Ovary_192hp_8_Phase3_Y_Z


title: FAD_30_Ovary_192h_5_Phase3_Y_Z


title: FAD_3_Ovary_192hp_5_Phase3_Y_Z


title: FAD_Control_Ovary_192hp_5_Phase3_Y_Z


title: FAD_30_Ovary_192h_7_Phase3_Y_Z


title: FAD_30_Ovary_192hp_6_Phase3_Y_Z


title: FAD_Control_Ovary_192hp_6_Phase3_Y_Z


title: FAD_3_Ovary_192hp_1_Phase3_Y_Z


title: FAD_Control_Ovary_192hp_2_Phase3_Y_Z


title: FAD_Control_Ovary_192hp_4_Phase3_Y_Z


title: FAD_Control_Ovary_192hp_3_Phase3_Y_Z


title: FAD_30_Ovary_192h_3_Phase3_Y_Z


title: FAD_30_Ovary_192h_4_Phase3_Y_Z


title: FAD_30_Ovary_192h_2_Phase3_Y_Z


title: FAD_3_Ovary_192h_8_Phase3_Y_Z


title: FAD_30_Ovary_192h_1_Phase3_Y_Z


title: FAD_3_Ovary_192h_6_Phase3_Y_Z


title: FAD_3_Ovary_192h_7_Phase3_Y_Z


title: FAD_Control_Ovary_192h_7_Phase3_Y_Z


title: FAD_3_Ovary_192h_1_Phase3_Y_Z


title: FAD_3_Ovary_192h_2_Phase3_Y_Z


title: FAD_Control_Ovary_192hp_1_Phase3_Y_Z


title: FAD_Control_Ovary_192h_1_Phase3_Y_Z


title: FAD_3_Ovary_192h_5_Phase3_Y_Z


title: FAD_50_Ovary_06h6h_4_X_Y_Z


title: FAD_Control_Ovary_192h_5_Phase3_Y_Z


title: FAD_3_Ovary_192h_4_Phase3_Y_Z


title: FAD_3_Ovary_192h_3_Phase3_Y_Z


title: FAD_Control_Ovary_192h_4_Phase3_Y_Z


title: FAD_Control_Ovary_192h_3_Phase3_Y_Z


title: FAD_Control_Ovary_192h_6_Phase3_Y_Z


title: 12-14-11_GRodgers_#6_HL_Mouse430_2_6_WT2

city: Bethesda

first: WeiPing

last: Chen

state: MD

address: Bldg 8, Room 1A11, NIDDK/NIH

department: GCL

institute: NIDDK/NIH

hyb_protocol: Following fragmentation, 10 ug of cRNA were hybridized for 16 hr at 45C on GeneChip Mouse Genome Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.

scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.

data_processing: RMA nomanization method of software Partek6.6

label_protocol: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).

growth_protocol: Mouse were collected from NIDDK animal core facility

extract_protocol: Trizol extraction of total RNA was performed according to the manufacturer's instructions.

treatment_protocol: RNA was isolated samples from KO and WT genotype

value: prostate

tag: strain

value: 50% 129/SV and 50% National Instites of Health Black Swiss

tag: genotype/variation

value: Wild type


title: FAD_Control_Ovary_192h_2_Phase3_Y_Z

value: FAD

value: CONTROL


title: 12-14-11_GRodgers_#1_HL_Mouse430_2_1_KO1

value: Olfactomedin 4 KO


title: FAD_50_Ovary_06h6h_3_X_Y_Z


title: 12-14-11_GRodgers_#2_HL_Mouse430_2_2_KO2


title: FAD_5_Ovary_06h6h_4_X_Y_Z


title: FAD_50_Ovary_06h6h_2_X_Y_Z


title: 12-13-11_GRodgers_#8_HL_Mouse430_2_8-W4


title: 12-14-11_GRodgers_#7_HL_Mouse430_2_7_WT3


title: FAD_50_Ovary_06h6h_1_X_Y_Z


title: 12-13-11_GRodgers_#5_HL_Mouse430_2_5-W1


title: FAD_5_Ovary_06h6h_2_X_Y_Z


title: 12-13-11_GRodgers_#4_HL_Mouse430_2_4-KO4


title: FAD_5_Ovary_06h6h_3_X_Y_Z


title: FAD_Control_Ovary_06h6h_2_X_Y_Z


title: FAD_5_Ovary_06h6h_1_X_Y_Z


title: FAD_Control_Ovary_06h6h_3_X_Y_Z


title: Patient 32, tumor

city: Frankfurt

first: Patrizia

last: Malkomes

address: Theodor-Stern-Kai 7

country: Germany

institute: University hospital frankfurt

hyb_protocol: Hybridization cocktail was prepared with Affymetrix hybridization kit materials, control oligonucleotides B2 and eukaryotic hybridisation controls. Hybridization was done at 45° at 60rpm for 18 hours. Fluidics washing was done using the Affymetrix Wash and Stain Kit (#900457), protocol FS450_0001.

scan_protocol: Arrays were scanned with Affymetrix Gene ChIP Scanner 3000 7G and images were processed using the Command Console.

data_processing:
The data were analyzed with R/Bioconductor version 3.0.1 using Affymetrix R-package (affy) with default analysis settings and normalized by RMA (quantile) using the Affymetrix power tools.
HuEx-1_0-st-v2.r2.pgf
HuEx-1_0-st-v2.r2.dt1.hg18.core.mps

source_name: tumor

label_protocol: After purification with QIAGEN MinElute Reaction Cleanup Kit (#28204), cDNA samples were fragmented and biotin labeled using the Encore Biotin Module (NuGEN).

extract_protocol: cDNA synthesis and amplification was performed using the Applause WT-Amp Plus ST RNA amplification system (NuGEN).

value: Tumor tissue


title: Mouse 4 Not treated 600 mm3

city: Birmingham

first: Joseph

middle: William

last: Wragg

state: West Midlands

address: Edgbaston

department: Institute of Biomedical Research

institute: University of Birmingham

hyb_protocol: 1.5 ug of Cy3-labelled cRNA (specific activity >10.0 pmol Cy3/ug cRNA) was fragmented at 60°C for 30 minutes in a reaction volume of 250 ml containing 1x Agilent fragmentation buffer and 2x Agilent blocking agent following the manufacturers instructions. On completion of the fragmentation reaction, 250 ml of 2x Agilent hybridization buffer was added to the fragmentation mixture and hybridized to an Agilent SurePrint G3 Mouse Gene Expression v2 8x60K microarray chip (G4852B) for 17 hours at 65 °C in a rotating Agilent hybridization oven.  After hybridization, microarrays were washed 1 minute at room temperature with GE Wash Buffer 1 (Agilent) and 1 minute with 37°C GE Wash buffer 2 (Agilent), then dried immediately by brief centrifugation.

scan_protocol: Slides were scanned immediately after washing on the Agilent DNA Microarray Scanner (G2565CA) using one color scan setting for 8x80k array slides (Scan Area 61x21.6 mm, Dye channel is set to Green and Green PMT is set to 100%).

data_processing: The scanned images were analyzed with Feature Extraction Software 9.1 (Agilent) using default parameters to obtain background subtracted and spatially detrended Processed Signal intensities.  Features flagged in Feature Extraction as Feature Non-uniform outliers were excluded.

source_name: 4T1 tumour

label_protocol: Cy3 labeled cRNA was prepared from 50ng RNA, using the Agilient low input, quick amp, one colour labelling kit according to the manufacturer's protocol, followed by RNAeasy column purification (QIAGEN).  Dye incorporation and cRNA yield were checked with the NanoDrop ND-1000 Spectrophotometer.

growth_protocol: 2.5x105 4T1-Luc cells suspended in Optimem (Gibco) and in a volume of 100 μL, were injected into the third mammary fat pad of anaesthetised 8-week-old female Balb/C mice. After a 1 week tumour establishment period, mice received either 40 mg sunitinib (Selleck Chemicals) per kg body weight in PBS and 3.72% DMSO or the drug vehicle only. At the experimental endpoint the tumours were resected and the endothelium extracted.

extract_protocol:
Tissue was minced and digested in DMEM containing 2 mg ml-1 collagenase type V (Sigma), 7.4 mg ml-1 actinomycin D (Sigma) and 30 kU ml-1 DNase I (Qiagen), shaking at 37°C for 1 hour. Endothelial cells were isolated from the digested single cell suspension by positive magnetic selection using 1x107/g sheep anti-rat IgG coated M-280 Dynabeads® (Invitrogen) conjugated to 2.5 μg rat anti-mouse PECAM-1 antibody (MEC13.3 clone, BD Falcon). The remaining digested tissue was collected as the bulk fraction
Total RNA was isolated from the endothelial isolates using the Qiagen miRNA easy kit according to the manufacturer's protocol.

tag: resected at

value: 600 mm3 in size

tag: tumour component

value: Bulk tumour

value: Treatment vehicle

tag: sensitivity to sunitinib up to day 8


title: FAD_50_Ovary_06h4h_4_X_Y_Z

value: OVARY


title: Mouse 4 Sunitinib treated 600 mm3

tag: treatment

value: 40 mg/kg Sunitinib

value: Sensitive


title: Mouse 3 Not treated 600 mm3


title: Patient 40, tumor


title: 12-13-11_GRodgers_#3_HL_Mouse430_2_3-KO3


title: FAD_3_Ovary_24h_2_Phase3_Y_Z


title: Patient 29, tumor


title: Patient 41, tumor


title: FAD_Control_Ovary_06h6h_4_X_Y_Z


title: Mouse 3 Sunitinib treated 600 mm3


title: Patient 24, tumor


title: FAD_Control_Ovary_06h6h_1_X_Y_Z


title: Patient 41, normal

source_name: normal

value: Normal tissue


title: FAD_50_Ovary_06h4h_2_X_Y_Z

value: ug/L


title: Mouse 1 Not treated day 9

value: Day 9 timepoint


title: FAD_50_Ovary_06h4h_3_X_Y_Z


title: Mouse 2 Not treated day 9


title: Mouse 1 Sunitinib treated day 9


title: Mouse 2 Sunitinib treated day 9


title: Mouse 5 Not treated bulk fraction

value: 1300 mm3 in size


title: FAD_50_Ovary_06h4h_1_X_Y_Z


title: FAD_5_Ovary_06h4h_3_X_Y_Z


title: FAD_5_Ovary_06h4h_4_X_Y_Z


title: Mouse 4 Not treated bulk fraction


title: Patient 23, normal


title: Patient 95

tag: idh1 status

value: Mutant

tag: phillips subtype

value: Proneural

tag: tcga subtype

value: Bevacizumab

tag: surgical status

tag: Sex

value: Male

tag: age

value: Off

tag: mgmt status

value: Non-methylated

tag: mmse

tag: rpa class

tag: who

tag: os time to event (months)

tag: os event type (0 = censored)

tag: pfs time to event (months)

tag: pfs event type (0 = censored)


title: Patient 40, normal

tag: tissue


title: Patient 29, normal


title: FAD_Control_Ovary_06h4h_3_X_Y_Z

tag: chemical

value: FAD

tag: dose

value: CONTROL

tag: exposure duration

tag: dosage unit

tag: age (month)

tag: arrayname

tag: featureextractiontime


title: Mouse 3 Not treated bulk fraction

tag: resected at

tag: tumour component

value: Bulk tumour

tag: treatment

tag: sensitivity to sunitinib up to day 8


title: Patient 24, normal


title: Mouse 3 Sunitinib resistant bulk fraction

value: Resistant


title: Mouse 2 Not treated bulk fraction

value: Treatment vehicle


title: Patient 92

tag: idh1 status

tag: phillips subtype

tag: tcga subtype

tag: surgical status

tag: Sex

tag: age

tag: corticosteroids

tag: kps

tag: mgmt status

value: Methylated

tag: mmse

tag: rpa class

tag: who


title: FAD_5_Ovary_06h4h_1_X_Y_Z

tag: chemical

tag: dose

tag: tissue

value: OVARY

tag: exposure duration

tag: dosage unit

tag: age (month)

tag: arrayname

tag: featureextractiontime


title: FAD_Control_Ovary_06h4h_4_X_Y_Z


title: CBPi_Treg (H0061159)

city: Cambridge

first: Barbara

middle: M

last: Bryant

state: MA

address: 215 First Street

institute: Constellation Pharmaceuticals

description: Sample name: H0061159

hyb_protocol: The fragmented and labelled ST-cDNA was added to the hybridization cocktail in accordance with the NuGEN guidelines for hybridization onto Affymetrix GeneChip® arrays. Following the hybridization for 18 hours at 45°C in an Affymetrix GeneChip® Hybridization Oven 640, the array was washed and stained on the GeneChip® Fluidics Station 450 using the appropriate fluidics script.

scan_protocol: The arrays were inserted into the Affymetrix autoloader carousel and scanned using the GeneChip Scanner 3000. Array scanning was performed according to the manufacturer's instruction (Affymetrix).

data_processing: Standard RMA background correction, quantile normalization and median polish summarization (Bolstad et al 2003) on the exon and transcript core probes, resulting in log2 expression estimates.  Affymetrix' Expression Console software was used, with default settings.

label_protocol: Total RNA was amplified using the NuGEN Applause? WT Amp Plus ST Amplification System. First-strand synthesis of cDNA was performed using a unique first-strand DNA/RNA chimeric primer mix, resulting in cDNA/mRNA hybrid molecules. Following fragmentation of the mRNA component of the cDNA/mRNA molecules, second-strand synthesis was performed and double-stranded cDNA was formed with a unique DNA/RNA heteroduplex at one end. In the final amplification step, RNA within the heteroduplex was degraded using RNaseH, and replication of the resultant single-stranded cDNA was achieved through DNA/RNA chimeric primer binding and DNA polymerase enzymatic activity. A modification step targeting the amplified single-stranded cDNA resulted in the generation of sense target (ST) cDNA product compatible with the Affymetrix GeneChip® Exon arrays. The ST-cDNA was purified for accurate quantitation and to ensure optimal performance during the fragmentation and labeling process. The ST- cDNA was assessed using spectrophotometric methods in combination with the Agilent Bioanalyzer. The appropriate amount of amplified ST-cDNA was fragmented and labeled using the Encore? Biotin Module. The enzymatically and chemically fragmented product (50-100 nt) was labeled via the attachment of biotinylated nucleotides onto the 3'-end of the fragmented ST-cDNA.

growth_protocol: Human naïve T cells were isolated and activated using anti-CD3/ anti-C28 in the presence of TGFb and IL-2 for 4 days (Treg) or anti-CD3/ anti-CD28 alone (TH0)

extract_protocol: Total RNA was prepared by using a Qiagen RNeasy kit with on-column DNase digestion according to the manufacturers instructions.

treatment_protocol: EP300/ CBP inhibitor was added at a final concentration of 4 mM

tag: cell line

value: Treg

tag: treatment

value: CBPi


title: Mouse 4 Sunitinib resistant bulk fraction

tag: resected at

tag: tumour component

value: 40 mg/kg Sunitinib

tag: sensitivity to sunitinib up to day 8


title: FAD_Control_Ovary_06h4h_2_X_Y_Z

value: ug/L


title: DMSO_Th0 (H0061162)

description: Sample name: H0061162

value: DMSO


title: FAD_50_Ovary_06h30m_4_X_Y_Z


title: DMSO_Treg (H0061158)

description: Sample name: H0061158


title: FAD_Control_Ovary_06h4h_1_X_Y_Z


title: Mouse 1 Sunitinib resistant bulk fraction

value: 1300 mm3 in size


title: FAD_5_Ovary_06h4h_2_X_Y_Z


title: Mouse 2 Sunitinib resistant bulk fraction


title: CBPi_Treg (H0061160)

description: Sample name: H0061160


title: FAD_50_Ovary_06h30m_3_X_Y_Z


title: Mouse 4 Sunitinib sensitive bulk fraction

value: Sensitive


title: DMSO_Th0 (H0061161)

description: Sample name: H0061161


title: DMSO_Treg (H0061157)

description: Sample name: H0061157


title: FAD_50_Ovary_06h30m_1_X_Y_Z


title: FAD_50_Ovary_06h30m_2_X_Y_Z


title: Mouse 5 Sunitinib sensitive bulk fraction


title: FAD_5_Ovary_06h30m_4_X_Y_Z


title: Mouse 4 Not treated EC fraction

source_name: 4T1 tumour associated endothelium

value: Endothelium


title: FAD_5_Ovary_06h30m_1_X_Y_Z

source_name: ovary tissue, fish exposed to various treatment conditions


title: Mouse 5 Not treated EC fraction


title: Mouse 2 Sunitinib sensitive bulk fraction


title: Mouse 3 Sunitinib sensitive bulk fraction


title: FAD_5_Ovary_06h30m_3_X_Y_Z


title: FAD_5_Ovary_06h30m_2_X_Y_Z


title: FAD_Control_Ovary_06h30m_4_X_Y_Z


title: Mouse 3 Sunitinib resistant EC fraction


title: FAD_Control_Ovary_06h30m_3_X_Y_Z


title: FAD_Control_Ovary_06h30m_2_X_Y_Z


title: FAD_50_Ovary_06h2h_2_X_Y_Z


title: FAD_50_Ovary_06h2h_3_X_Y_Z


title: FAD_Control_Ovary_06h30m_1_X_Y_Z


title: FAD_50_Ovary_06h2h_1_X_Y_Z


title: FAD_5_Ovary_06h2h_3_X_Y_Z


title: Mouse 2 Not treated EC fraction


title: Mouse 4 Sunitinib resistant EC fraction


title: Mouse 1 Sunitinib resistant EC fraction


title: Mouse 5 Sunitinib sensitive EC fraction


title: Mouse 3 Sunitinib sensitive EC fraction


title: Mouse 2 Sunitinib resistant EC fraction


title: Mouse 4 Sunitinib sensitive EC fraction


title: FAD_Control_Ovary_06h2h_2_X_Y_Z


title: FAD_5_Ovary_06h2h_4_X_Y_Z


title: FAD_50_Ovary_06h2h_4_X_Y_Z


title: FAD_Control_Ovary_06h2h_4_X_Y_Z


title: FAD_50_Ovary_06h1h_3_X_Y_Z


title: FAD_Control_Ovary_06h2h_1_X_Y_Z


title: FAD_5_Ovary_06h2h_2_X_Y_Z


title: FAD_50_Ovary_06h1h_4_X_Y_Z


title: Mouse 2 Sunitinib sensitive EC fraction


title: FAD_5_Ovary_06h2h_1_X_Y_Z


title: FAD_5_Ovary_06h1h_1_X_Y_Z


title: FAD_5_Ovary_06h1h_2_X_Y_Z


title: Mouse 3 Not treated EC fraction


title: FAD_5_Ovary_06h1h_3_X_Y_Z


title: FAD_Control_Ovary_06h2h_3_X_Y_Z


title: FAD_5_Ovary_06h1h_4_X_Y_Z


title: FAD_Control_Ovary_06h1h_4_X_Y_Z


title: FAD_50_Ovary_06h1h_1_X_Y_Z


title: FAD_Control_Ovary_06h1h_1_X_Y_Z


title: FAD_Control_Ovary_06h1h_3_X_Y_Z


title: FAD_Control_Ovary_06h1h_2_X_Y_Z


title: FAD_50_Ovary_24h6h_4_X_Y_Z


title: FAD_50_Ovary_24h6h_3_X_Y_Z


title: FAD_50_Ovary_06h1h_2_X_Y_Z


title: FAD_50_Ovary_24h6h_2_X_Y_Z


title: FAD_50_Ovary_24h6h_1_X_Y_Z


title: FAD_Control_Ovary_24h6h_4_X_Y_Z


title: FAD_Control_Ovary_24h6h_3_X_Y_Z